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CHAPTER 1 INTRODUCTION
What is Venous Thromboembolism (VTE)?
Venous Thromboembolism (VTE) is a cardiovascular disorder that results from a
blood clot (thrombus) that forms within a vein. When a blood clot breaks loose and
travels in the blood, it is called a venous thromboembolism (VTE). VTE is the third
most common cardiovascular disease after heart attack and stroke[1] with roughly
900,000 instances a year in the US[2]. Centers for Disease Control and Prevention
(CDC) suggests that 60,000‐100,000 American patients die of VTE in hospitals each
year. Their reports also indicate that 10‐30% of patients die within one month of
diagnosis.1
There are two common types of diagnosed VTE disorders:
Deep vein thrombosis: when the blood flow changes or slows down, a deep vein
thrombosis (DVT) which is a blood clot forms in the deep veins of the leg.
Pulmonary embolism: when a DVT breaks off (embolizes) and flows towards the
lungs, it can partially or completely block one or more arteries (embolism). This can
become a life‐threatening pulmonary embolism (PE), i.e. a blood clot in the lungs.

1
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2
The abbreviation DVT/PE refers to a VTE in which a deep vein thrombosis (DVT)
moves to the lungs (PE or pulmonary embolism).
DVT and PE are serious and lethal conditions that can recur frequently. If these
conditions are not diagnosed early, they may lead to long‐term complications such
as chronic thromboembolic pulmonary hypertension (CTPH) or the post‐
thrombotic syndrome (PTS).

Figure 1 ‐ Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

Symptoms and Diagnosis of DVT/PE
An episode of DVT usually affects one side of the body at a time where the blood
clots occur in the large veins located in the lower leg and thigh. The following are
the most common symptoms of DVT that occur in the affected parts of the body:
 Swelling

3
 Pain
 Tenderness
 Redness of the skin
Unfortunately, about half of the people with DVT have no symptoms at all.
Pulmonary embolism (PE) can also happen without any symptoms of a DVT.
However, signs and symptoms of PE can include:
 Unexplained difficulty in breathing
 Faster than normal or irregular heart beat
 Faster than normal breathing
 Chest pain or discomfort, which usually worsens with a deep breath or
coughing
 Anxiety
 Coughing up blood
 Very low blood pressure, lightheadedness, or fainting
DVT is often diagnosed using:
 Duplex ultrasound—This method uses sound waves to evaluate the flow of
blood in the veins.
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 Venography—If the duplex ultrasound does not provide a clear diagnosis, a
venogram‐ a type of X ray‐ is used to look at the veins to see if clots are
present.
 D‐dimer—a blood test that can be used to rule out a clot.
DVT also can be diagnosed using the following, less frequently used tests:
 In many cases, Magnetic Resonance Imaging (MRI) can provide information
that would not show up on an x‐ray. This test is being used more frequently
to diagnose DVT.
 A computed tomography scan is a special type of x‐ray that can provide
pictures of structures inside the body; however, this test is rarely used to
diagnose DVT.
Tests to find the location of and damage to the lungs caused by a PE include:
 Computerized Tomography (CT scan) of the lung: a special type of x‐ray that
can provide pictures of structures inside the body.
 Pulmonary ventilation or perfusion scan: a special test that looks at how the
lung is working and if it is getting enough blood.
 Pulmonary angiogram: the injection of a dye into the heart and then an x‐ray
to look for clots in the lung.
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Unfortunately, there are other conditions with symptoms similar to those of DVT
and PE. For example, muscle strains and swelling of veins close to the skin
(superficial veins) can produce the same symptoms as DVT. Heart attack and
pneumonia also produce symptoms like those of PE. Therefore, it is difficult to
diagnose either condition without the aforementioned tests.2
Naturally if a patient is admitted to the hospital with symptoms associated with
DVT/PE, depending on the situation, the doctors could start treatment with
anticoagulants while ordering and waiting for the imaging test results.
Risk Factors for Venous Thromboembolism (VTE)
Although VTE episodes can happen in men and women of various races and
ethnicities at any age, there are certain factors that increase the likelihood of VTE
instances. DVT/PE episodes are most common in the following circumstances:
 Patients that undergo major surgery (general surgery as well as orthopedic
surgery)
 Cancer patients (especially at those at advanced levels of cancer)
 Patients with autoimmune disorders (e.g. lupus)
 Patients with multiple trauma

2
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 Patients with fractures in pelvis, hip, or long bones
 Hospitalized patients
 Paralyzed patients
Other triggers of DVT/PE that are specific to women are pregnancy and using
oral contraceptives or hormone treatments for menopause symptoms. DVT/PE risk
is greater for pregnant women if they are pregnant with twins or have other
medical issues such as cancer or serious infection during their pregnancy. VTE risk
will also increase as the maternal age increases.
It is critical for medical professionals to take preventive measures when the
aforementioned factors exist. However, there are additional factors that are not as
critical but a combination of two or more of them can justify preventive treatment.
These factors are listed below:
 Thicker than normal blood
 Previous episodes of VTE
 Obesity
 Age of 40 years old or more (most common in adults 60 and older)
 Family history of VTE
 Genetic conditions that increase the chance of blood clotting
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Prevention and Treatment of DVT/PE
VTE incidents are often preventable at hospitals through risk assessment
techniques. Healthcare professionals can often discern the risk of VTE incidence by
collecting a patient’s information such as previous episodes of VTE, age, weight, life
style, family history, and medications. By assessing the risk of VTE and identifying
high‐risk patients, they can prevent VTEs by stopping the developments of blood
clots in these patients. According to the American Heart Association (AHA),
“adequate prevention measures in high‐risk patients can prevent VTE in one of 10
patients”3. Therefore, VTE prevention is highly beneficial for public health because
of its potential for saving patients’ lives and decreasing healthcare costs.
Two ways of preventing and treating DVT are using medication or using
compression devices. It is also advised that patients that undergo surgery get up
quickly from bed after the surgery. Treatment through medication includes
receiving anticoagulants (blood thinners). Although these medications are called
blood thinners, they do not actually make the blood any thinner. They target the
clotting process of the blood and prevent the clots from getting larger. Another
option is using strong clot busters to break up the clots. The most frequently used
medications are heparin, low molecular weight heparin (LMWH), and warfarin. As

3
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a side effect, these medications can cause bleeding; therefore, anyone taking them
must be monitored to prevent unusual bleeding.
 Heparins
Usually, treatment of a clot starts with heparin. Heparin is a powerful
anticoagulant and is either given through Intravenous or IV (a needle placed in
the vein) or administered through an injection to stop clotting more quickly.
Since high doses of heparin can cause bleeding, heparin is usually administered
only in a hospital.
 Low Molecular Weight heparins (LMWH)
Although LMWH is similar to heparins, it is made from shorter chains of
polysaccharide. LMWH is administered through an injection under the skin
(subcutaneous or shortly sub‐q). People who take LMWH do not generally
require frequent monitoring or blood tests; therefore, they can take the
medication while at home.
 Warfarin
Warfarin (Coumadin™) is a medicine that is taken orally. Since warfarin takes
some time to become effective, it usually is begun while a person is taking other
medications to stop clotting. Once it reaches an effective level, patients can stop
other medications and take only warfarin, but they need to have regular blood
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tests to ensure they are not at risk of bleeding. Warfarin can have interactions
with many drugs or foods; hence, consultations should be made to ensure the
safety of the patient.
 Compression stockings
Graduated compression stockings are recommended from time to time to
prevent DVT and reduce swelling and pain.
 Surgery
In severe cases, clots might need to be removed surgically. To prevent clots
from traveling towards the lungs, a filter is placed in the inferior vena cava which
is the body’s largest vein. In other procedures, large blood clots could be
removed from the vein, or clot busters could be injected in the vein or lung
artery.
Other medications used for treating DVT are tablets such as Apixaban,
Dabigatran, Rivaroxaban, and Edoxaban. Thromboprophylaxis (i.e. heparin /
enoxaparin)

is

also

recommended

for

non‐pregnant

patients

without

contraindications (major bleeding, low platelets, creatinine clearance < 30 mL/min)
who are >18 years[3].
Pulmonary embolism is a serious problem and requires emergency treatment. In
more severe or life‐threatening PEs, thrombolytics, which are medications such as
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a tissue plasminogen activator (TPA) that can dissolve the clot, and anticoagulants
that prevent more clot build‐ups should be used. Sometimes surgery will be needed
for patients who are at greater risk of a new PE.4
Policymakers such as US Surgeon General, the Centers for Medicare and
Medicaid Services5, and the National Quality Forum6 have deemed VTE a major
threat to patient safety. Therefore, there are numerous programs funded by all
sorts of organizations (Government based, Insurance companies, etc.) that are
aiming to help reduce VTE incidents at hospitals. Needless to say, the first step to
achieving this goal and improving the quality of care is to measure the instances of
VTE accurately and in a timely fashion.
Measuring DVT/PE Rates
Historically, DVT/PE rates for inpatients has been measured using administrative
or billing data based on a modified version of Agency for Healthcare Research and
Quality (AHRQ) PSI#12. Patient Safety Indicator or PSI#12 is one of the components
of PSI#90 which was defined by AHRQ as a composite measure to assess patient
safety. PSI#90 includes the following indicators which contribute to the composite
indicator through weights assigned to each indicator:

4

CDC Website: http://www.cdc.gov/ncbddd/dvt/treatments.htm
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Centers for Medicare and Medicaid Services. Press release, April 14 2008. http://www.cms.hhs.gov
National Quality Forum. Press release, May 15 2008. http://www.qualityforum.org
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 PSI #03 Pressure Ulcer Rate
 PSI #06 Iatrogenic Pneumothorax Rate
 PSI #07 Central Venous Catheter‐Related Blood Stream Infection Rate
 PSI #08 Postoperative Hip Fracture Rate
 PSI #09 Postoperative Hemorrhage or Hematoma Rate
 PSI #10 Postoperative Physiologic and Metabolic Derangement Rate
 PSI #11 Postoperative Respiratory Failure Rate
 PSI #12 Postoperative Pulmonary Embolism or Deep Vein Thrombosis Rate
 PSI #13 Postoperative Sepsis Rate
 PSI #14 Postoperative Wound Dehiscence Rate
 PSI #15 Accidental Puncture or Laceration Rate

By AHRQ definition, PSI#12 applies only to post surgery patients. Henry Ford
Health System (HFHS) uses a modified version of the PSI#12 for all patients
including both surgical and medical patients.
The validity of using AHRQs PSI#12 to measure DVT/PE harm has been discussed
in many papers in the past decade; however, there is considerable variability in the
reported results. Birman‐Deych, et al. used billing data of arterial fibrillation
patients and reported a sensitivity of 61% and a positive predictive value (PPV) of
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72% with negative predictive value (NPV) and specificity of 99% [4]. White, et al.
reported 80% sensitivity and 31% positive predictive value focusing on pregnant
patients at risk of getting DVT/PE [5]. Among the papers that focused on surgery
patients, Henderson, et al. found the sensitivity of the PSI#12 to be 87% with a PPV
of 55% [6]. In other studies, Zhan, et al. reported PSI#12’s sensitivity and PPV of
74% and 35% [7], and Romano, et al. reported it to be only 56% sensitive with a
PPV of just 22% using Veterans Affairs patient data [8]. Among the papers that
applied the PSI#12’s logic to medical and surgery patients, Heckbert, et al. reported
sensitivity of 86% and PPV of 75% [9] while Cushman, et al. reported PPV of 79%
[10], and White, et al. reported a better performance for the PSI#12 with sensitivity
and PPV of 96% and 79% [8]. Leibson, et al. reported a lower sensitivity of 74% with
the PPV of only 35% [11], and finally, White, et al. found the PSI#12’s NPV to be at
95% [12]. Table 1 summarizes this comparison.
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Table 1 ‐ PSI#12 Validation ‐ Summary
Author(s)
Birman‐Deych et al., 2005
White, Brickner, & Scannell,
2004
Henderson et al., 2009
Zhan, Battles, Chiang, &
Hunt, 2007
Romano et al., 2009
Heckbert et al., 2004
Cushman et al., 2004

White et al., 2009
Leibson et al., 2008
White, et al., 1998

Patient Population
Medicare beneficiaries aged 20 to 105 years
who had atrial fibrillation.
VTE either during pregnancy or the 6‐week
postpartum period
Post‐Surgery
Post‐Surgery
Post‐Surgery VA Patients
Medical and surgery
participants of the Atherosclerosis Risk in
Communities study and the Cardiovascular
Health Study
Data from 47 Hospitals Participated in PSI
Validation Project

Sensitivity PPV
61%
72%
80%

31%

87%
74%

55%
35%

56%
86%
62%

22%
75%
79%

79%

44%

74%
Patients After primary hip and primary knee 100%
arthroplasties

NPV
99%

35%
68% 95%
To
100%

Although using billing data for measuring DVT/PE harm is cheap, and the data is
readily available, this method comes with a few shortcomings. As mentioned
above, using billing data will provide widely varying levels of accuracy depending
upon the co‐morbidity. In addition, there are significant delays from the time of
diagnosis and treatment until the billing data becomes available for analysis. For
example, an analysis of 9 months of billing data at Henry Ford Health System
showed that it took an average of three weeks after discharge for the billing data
to become available. In addition, in 21% of the cases, this process took a month or
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longer. Figure 2 shows the distribution of the time that it took to code and bill a
hospital account after discharge.

Figure 2 ‐ Distribution of Time to Code a Hospital Account after Discharge

The impact of a lag caused by using billing data can be shown using a hypothetical
hospital stay of three months. If a VTE episode happens in week one of a 3 months
stay, the VTE case will only appear in the billing data 3.5 months after the incident.
The total delay in studying an incident includes the time from onset until discharge
plus the billing processing delay as illustrated in Figure 3.
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Hypothetic Length of Stay (3
One

One

Average time to bill (3

PSI#12 lags behind (3.5
DVT/PE

Earliest

time

PSI#12 can detect
Hospital
Figure 3 ‐ Demonstrate how PSI#12 lags for a hypothetical DVT/PE episode

The unavoidable extended lag reduces the potential value of this data in
improving care and educating medical personnel about patient safety. Imagine a
medical doctor talking to his/her interns or residents who review cases of DVT/PE.
There is a huge difference between reviewing cases of DVT/PE that happened last
month in the hospital and DVT/PE episodes that happened over the weekend to
patient XYZ in room 1234 in bed B. In the latter situation, they can quickly review
medical charts that are current and discuss why it happened and how to it can be
prevented in similar situations.
In this research, the aim was to overcome the shortcomings of measuring the
VTE incidents with billing data by developing a near real‐time VTE harm
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measurement using Electronic Medical Records. A VTE risk assessment model was
also developed in the EHR that is capable of real‐time patient risk assessment based
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CHAPTER 2 NEAR REAL‐TIME VTE HARM MEASUREMENT USING EHR
In this chapter, we first discuss some of the main challenges and limitations that
bear on using Electronic Health Records in the identification of DVT/PE instances.
Then, we introduce our proposed model and discuss how this model overcomes
the challenges of the historical model. After that, a comparison of the results of the
PS#12 model and our proposed model will be presented. Finally, we conclude the
discussion by linking our model to practice and suggesting how it can be used at
the hospital.
Using EHR to measure DVT/PE Harm
Limitations and challenges of using EHR to find DVT/PE harm
Challenge 1: First, it is essential to note that each EHR implementation and
rollout in diverse hospitals is different from another. Even when different hospitals
use the same software product from a specific vendor, the implementation could
still be different. They often customize the system, turn the functionalities on or
off, or choose to prioritize implementations of modules differently. The main tool
to diagnose DVT/PE is imaging tests such as Doppler, Duplex or Chest CT Scan for
PE. In our study at HFHS, like many other hospitals, the imaging results are not yet
a part of the EHR system. The results are stored in another system as image files,
and hence not searchable or extractable. Having the imaging results in the EHR
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system will make a huge difference in identifying DVT. Until that time, one of the
messages this research tries to convey is that current use of partial information in
EHR could still produce real time results that are significantly better than what is
currently available through billing.
 Challenge 2: In theory, reporting could be done in real time using EHR; however,
it is not value‐adding in practice in the case of DVT/PE harm measurement. In
addition, giving physicians and nurses access to run the report on‐demand could
overload the live system which is needed in real‐time to save lives. Instead, the
model we develop will run on a backup of another backup of the live system
which lags by 24 to 48 hours depending on the time of day the incident
happened.
 Challenge 3: One other issue was to identify medications used for DVT/PE
treatment and find a way to distinguish between the treatment of clots and
prophylaxis dosages of the medications to prevent clots. An analysis found that
the medications used for treating DVT/PE overlap with many other problems,
conditions and procedures. These include as Cerebrovascular Arrest, Arterial
Fibrillation (A‐fib), Mechanical Valve Replacement, Arterial Valve Replacement,
Left Ventricular Assisted Device (LVAD), Extracorporeal Membrane Oxygenation
(ECMO), Nonischemic Cardiomyopathy (NICM) and so on. Because these
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treatments are not unique to DVT/PE harm, one cannot call the administration
these medications an indication of DVT/PE harm.
 Challenge 4: Another challenge was to distinguish between harm, “at risk” of
harm and “suspected” harm. At HFHS, a problem list is used in the EHR. When
doctors order medications or procedures, they must select one or more specific
problems from the problem list that they have identified in the patient.
Unfortunately, when in doubt, the doctors specify a problem to order the
diagnostic tests or medications for treatment; however, if the results come back
as negative, they should stop the treatment order and remove the problem
from the patient’s records. Preliminary analysis showed that this updating is not
always followed. The other issue arises when a patient is at risk of the problem
but does not yet have a DVT. Doctors will select DVT as the problem on the list
and order prophylaxis dosage of the treatment but this data point needs to be
weeded out by a harm identification model.
 Challenge 5: One critical concern was to distinguish between pre‐existing and
hospital acquired harm. This can potentially make a significant difference for the
hospital in terms of the money received for treatment of the patient. Depending
on the case, if the problem is pre‐existing to admission, the hospital can be extra
compensated for the treatment of an illness with complication or with major
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complication. This is because rates for treating conditions are higher when
conditions are labelled “with complication”, which can add more than $1,500 to
the bill. However, if this happens inside the hospital, the hospital would be
accountable for the extra treatment of the patient and the resulting expenses.
There is a field in the problem list to specify if a problem was present on
admission (POA) or not. Preliminary analysis and studies showed that this data
field is not reliable. Therefore, other methods were needed to determine if
DVT/PE was present upon admission.
 Challenge 6: Another task was to distinguish between thrombosis of other veins
versus deep veins in the EHR. There are cases in which the physician suspects
that the patient who has been admitted with pain and swelling in their legs has
a DVT. The doctor immediately adds this to the problem list and orders imaging
tests and starts the treatment. The imaging test may then reveal that it was, in
fact, a case of a superficial vein thrombosis and not a deep vein thrombosis.
Nevertheless, since it is still a thrombosis in a vein, they do not stop the
treatment. This is an extremely hard case to identify, because it was categorized
as a DVT and treated as a DVT; however, it was not a DVT. The only way to find
these cases is to read the results of the imaging test which are not accessible
through the EHR.

21
 Challenge 7: There is need for a gold standard to reach a final diagnosis for each
case. Chart reviews were selected as the gold standard but they are expensive
and time consuming to carry out. Experienced staff must dedicate precious time
to do chart reviews which is highly variable in length. Each chart review can take
from a few minutes up to a few hours. An experienced nurse can complete an
average of one chart review per hour. This limits our ability to select a
reasonable sample size for this study.
Developed model to identify cases of DVT/PE harm using EHR
DVT/PE treatment options were identified through preliminary studies and
meetings with physicians inside HFHS. The following is a summary of the
medications and their dosages that are used in HFHS to treat DVT/PE;
•

Heparin IV: 25,000 units

•

Argatroban: any dosage

•

Enoxaparin (Lovenox): 40 mg if given at least Bi‐Daily or >40 mg at any

frequency
In the absence of diagnostic imaging results, a procedural logic was developed
to identify DVT/PE harm. The logic started out simple. If a DVT/PE problem is added
to the problem list of a patient during a hospital stay, and then they receive
treatment dosages of the above medications, it should mean that the patient had
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an episode of DVT/PE while in the hospital. However, as pointed out earlier, the
problem list has accuracy problems and many of the medications are also used for
patients with heart problems. Another addition to our identification model is
checking to see if any imaging procedures were ordered for the patient.
To find out if the problem was present on admission or not, we looked at the
time when the patient first received the treatment. In theory, there should be a
threshold for the time it takes from the moment of admission until the time a
patient receives treatment dosages of the listed medications that best identifies
whether there was a pre‐existing condition of the DVT/PE, POA. For preliminary
studies, 24 hours was selected as the threshold. If a patient had DVT/PE selected
on the problem list and received the treatment within the first 24 hours of
admission, the logic classified it as a pre‐existing DVT/PE. However, if the treatment
started more than 24 hours after admission to the hospital, the proposed logic
labeled it as a hospital‐acquired harm.
Figure 4 shows the original comprehensive logic that was developed to be tested
for validity.
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Figure 4 ‐ Original Comprehensive Logic for finding VTE instances
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The above figure illustrates the decision logic with the number of cases in each
category in parenthesis (till 8/19/2014). The first node checks to see whether a
patient received any treatment within the first 24 hours or not. If they received
one, the model identifies them as present on admission VTEs. Then it checks to see
if the patient received any Argatroban treatment or not. Argatroban treatment was
placed near the top since there are only a few other problems that have treatment
overlaps with VTE using Argatroban. Other decision nodes that were also
considered include any imaging study orders (such as venous doppler, venous
duplex, CT scan of chest or pulmonary ventilation (V) and perfusion (Q) or VQ
scans), and existence of heart problems that could have Enoxaparin treatment
overlaps.
Final model
Figure 5 illustrates the final model showing three selected main indicators of
harm. To check the validity of the model, a stratified random sample of 434 cases
was selected and analyzed. Four experienced nurses were in charge of the blind
sample chart reviews. They were provided with the ID of the patient and the
hospital stay that needed to be reviewed, identified by admission and discharge
time. Any patient younger than 18 years old was removed from the study. Since
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the results were to be checked against the modified PSI#12 method, any hospital
account that was not coded by billing was excluded from the study as well.
After the analysis and chart reviews, it was confirmed that 24 hours was the
threshold that created the best cut‐off for identifying the POA condition. In no case
was DVT/PE found to be present on admission and yet, the patient started the
treatment after 24 hours. Furthermore, neither type of the VTE treatment
(Argatroban, heparin drip, Enoxaparin, etc), existence of any imaging study or
present heart problem made any improvements in the performance of the model
and hence were removed from the final model.
The model first looked at the problem list. If the DVT/PE was added to the
problem list in that episode, and if the patient had received treatment after the
first 24 hours from admission, this model calls it a DVT/PE case.

Figure 5 ‐ Simplified and Final Model
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Findings and comparison of the results with the current method
Table 2 summarizes the results of the experiment. Asterisk‐marked (single or
double) cells indicate results significantly different from the ones obtained for the
modified PSI#12 using 1‐α=0.95. Our proposed logic is more than twice as sensitive
as the current PSI#12 (84% vs only 38%). It also outperforms the PSI#12 in Negative
Predictive Value (NPV) (99% vs. 95%). However, PSI#12 showed slightly better
results than the proposed logic for Positive Predictive Value, PPV and specificity.
However, the differences were not statistically significant in both cases.
In comparison, modified PSI#12 found 15 fewer true VTE cases (27 vs 12) which
are all false negatives. However, the proposed logic found 8 more false positives
than the modified PSI#12 (12 vs 4). The main error was that the model labeled a
case as DVT/PE and harm when, in fact, the illness was present on admission. Two
cases had a history of both DVT and PE, three cases had a history of DVT and in one
case the patient was admitted with the history of PE. Treatment of other veins as
DVT resulted in 3 cases of false positives. Prophylaxis for DVT, prophylaxis for PE,
ruling‐out DVT and ruling‐out PE each generated one false positive case for a total
of 4 more false positives.
Figure 6 gives another perspective of how our logic model, the modified PSI#12
and the chart review results compare to one another using a Venn diagram. In the
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Venn diagram, each circle represents a method of identification of DVT, and the
numbers inside a circle are the number of cases of harm identified by that method.
For example, number 10, which is covered by all three circles, represents 10 cases
of VTE harm that were identified by all three methods. Any number outside the
“Actual” circle is considered a false positive, either identified by PSI#12, the
proposed logic model or both. Of the false positives, two were shared by both the
logic model and PSI#12. Two were unique to PSI#12 and 10 were unique to the logic
model.
Table 2 ‐ Results of the Developed Model and the alternatives of the model
Modified PSI#12 (Apply PSI#12 to Both Surgical and Medical Patients)
Sensitivity:
38% (95% CI=21‐54%)
Positive Predictive Value:
75% (95% CI=54‐96%)
Specificity:
99% (95% CI=98‐100%)
Negative Predictive Value:
95% (95% CI=93‐97%)
Proposed Real‐Time Logic:
Sensitivity:
84% (95% CI=72‐97%) **
Positive Predictive Value:
69% (95% CI=55‐84%)
Specificity:
97% (95% CI=95‐99%)
Negative Predictive Value:
99% (95% CI=98‐100%) **
Alternative Logic: Receiving Meds and No Heart Problem
Sensitivity:
72% (95% CI=56‐87%) **
Positive Predictive Value:
15% (95% CI=9‐21%) *
Specificity:
67% (95% CI=63‐72%) *
Negative Predictive Value:
97% (95% CI=95‐99%)
Alternative Logic: Only Problem List
Sensitivity:
94% (95% CI=85‐100%) **
Positive Predictive Value:
38% (95% CI=27‐49%) *
Specificity:
88% (95% CI=84‐91%) *
Negative Predictive Value:
99% (95% CI=99‐100%) **
Alternative Logic: Ignoring Problem List
Sensitivity:
88% (95% CI=76‐99%) **
Positive Predictive Value:
23% (95% CI=15‐30%) *
Specificity:
76% (95% CI=72‐80%) *
Negative Predictive Value:
99% (95% CI=97‐100%)
Alternative Logic: Ignoring POA condition (Receiving Treatment in the First 24hrs of Admission)
Sensitivity:
91% (95% CI=81‐100%) **
Positive Predictive Value:
49% (95% CI=36‐62%)
Specificity:
92% (95% CI=90‐95%) *
Negative Predictive Value:
99% (95% CI=98‐100%) **
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* Worse than the corresponding value for modified PSI#12- Statistically
significant (1-α=0.95)
** Better than the corresponding value for modified PSI#12- Statistically
significant (1-α=0.95)

Figure 6‐ Compare three methods – Venn Diagram
A few WHAT‐IF scenarios were also evaluated to determine what happens if all
the information used in the proposed model was not accessible. The results of this
scenario analysis are summarized in Table 2. Starting from the bottom of the table,
if the first administration time of VTE treatment was not accessible, specificity
would decline (91% and the number of false positives would increase from 15 to
30). Not surprisingly, this version of the model will often incorrectly categorize pre‐
existing VTE cases as harm occurring in the hospital.
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If the problem list data was not accessible for any reason, the judgment could be
made using treatment data and the POA condition. In that case, PPV and specificity
suffer significantly (only 23% and 76%). Not surprisingly, the number of false
positives significantly increased to 96 cases. This happens because the treatment
overlaps with many other conditions.
If only the problem list was used for measuring VTE harm, again PPV and
specificity would suffer (38% and 88%) with 49 false positive cases. This number of
false positives was mainly due to having many cases of patients being “at risk” of
VTE or thrombosis of other veins and receiving “treatment” dosages of selected
anticoagulants when, in fact, the patient did not have DVT.
If just receiving the treatment was used to identify VTE cases, this would have to
be coupled with a filter to eliminate patients who had cardiac dysrhythmia or acute
myocardial infarction. PPV would have declined dramatically to only 15% with a
specificity of 67%.
Figure 7 depicts how the two methods of DVT/PE harm measurement, Billing and
the Logic Model compare to each other over 14‐month period. The Y axis
represents number of VTE harm instances per 1000 patient days. The red dotted
line is the expected real harm rates calculated by interpolating the numbers from
the two methods using the over/under reported proportions obtained in the chart
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reviews. From the chart reviews, PSI#12 and our logic respectively found 16 and 39
cases as compared to the 32 cases that were found in chart reviews. From these
figures, we can estimate that PSI#12 finds 50% fewer DVT/PE cases while our logic
model finds 21% more.

Figure 7 – Compare Three Methods ‐ Trends

Link to practice and how the model could be used
With the predictive value of the model verified, we investigated how
implementation of the model might impact practice. One use of the model would
be to improve diagnosis documentation. For example, a DVT/PE problem should be
removed from the problem list of the patient if the DVT/PE has been ruled out by
the imaging tests; however, chart reviews revealed that this record update does
not always happen.
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This model also can help improve resident education program. Senior physicians
can review VTE cases with their residents soon after each instance of VTE while
patient is still in the hospital. Comparted to the old model that could only provide
this information long after patient discharge which marginalizes education value of
the specific cases.
Our analysis also indicated opportunities for improvement in care. In a couple of
cases, thrombosis of superficial veins was treated as DVT while they should not
have been. This also offers an opportunity for improved education of medical staff.
Another example for usage of the model involves studying a policy change
specifically at the main campus of Henry Ford Hospital. There is a recommendation
to order compression stockings for every bed to reduce the time that takes for
delivering them to the patients. It is suggested that the unavailability of these
stockings is a contributing factor in developing DVT in the main campus. At this
location, the rate of DVT is higher than the other three HFHS hospitals which have
these stockings available at every bedside. Without having this model, it would be
almost impossible to carry out this research study. It is the timeliness, accuracy,
and comprehensiveness of this model that can enable such analysis.
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CHAPTER 3 VTE RISK ASSESSMENT ‐ IMPLEMENTATION IN EHR
This chapter describes selection of a well‐known VTE risk assessment model and
implementing it in the EHR to assess patients for risk of developing a VTE in real‐
time. The contribution in this chapter is the process to translate and replace factors
used in a manual risk assessment model to information present in EHR, and
presentation of retrospective data analysis that shows the effectiveness of the real‐
time transformed model.
Background and its importance
As mentioned before, VTE is a serious problem and in the past century,
physicians and researchers have tried to create new ways to treat them. Heparin
was discovered and introduced in 1916 by Jay McLean and William Henry Howell
and then produced in a way to be safely used in treating VTEs in 1936 by Connaught
Medical Research Laboratories until today. Heparin and related drugs have enables
tremendous improvements in how VTEs are treated and eliminated.
Nevertheless, VTE is still deadly today. It is still costly for both patients and
hospitals to treat, and can leave patients with lifetime disabilities and
repercussions. Therefore, being proactive is key and any risk assessment model
must have a low type I error, false negative rate.
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Although pharmacological prophylaxis has proven to be effective, it significantly
increases the risk of bleeding for hospitalized patients, especially when the central
nervous system is engaged, like in stroke patients[2, 13]. Therefore, it is important
for risk assessment models to have a low type II error as well.
In summary, putting patients at risk of internal bleeding should be avoided, but
it is generally preferred to the other choice of putting patients at risk of VTE.
Therefore, VTE risk assessment models must give priority to a lower type I error
rather than a type II error. It is much better to put a few more patients on
pharmacological prophylaxis rather than missing the same number of patients who
are at risk of getting a VTE.
In the past few decades, there has been an incredible amount of research on
causes of thrombosis and identifying the factors that increase the risk of
occurrence. It was only in the last 10‐15 years that researchers started to advocate
individualized patient risk assessment to dive deeper into identifying VTE risk in
surgical patients[14‐17]. The results looked promising and thus, medical treatment
shifted towards individual VTE risk assessment. For example, England made it
mandatory in June 2010 to assess individual patients for VTE risk and created a
database for hospitals to capture patients’ VTE risk assessment data7.

7

https://www.england.nhs.uk
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It had been believed that the same VTE risk factors were associated with
coronary artery disease risk factors. However in the past decade, analysis of large
registries of PE patients (ICOPER: International Cooperative Pulmonary Embolism
Registry) and DVT/PE patients (RIETE: Registro Informatizado de la Enfermedad
Trombo‐Embolica venosa) has shown that the factors are actually quite
different[18]. Recent published works have tried to identify these specific risks.
Currently, it is believed that there are three main underlying reasons that cause
venous thromboembolism. These are stasis of the blood flow, damage to the
vascular endothelial cells, and hypercoagulability. It can be argued that any
problem that can cause any of the previously mentioned reasons can in turn
increase the risk of developing thrombosis. At the same time, these problems can
be temporary, non‐modifiable or modifiable[18]. Based on this perspective, the
major agreed upon risk factors are summarized in the below table[19, 20]:
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Table 3 ‐ Venous Thromboembolism Risk Factors

Modifiable
Factors
Non‐Modifiable
Factors

Temporary
Factors

Moderate Risk Factors
 Oral contraceptive pills

Weak Risk Factors
 Obesity
 Varicose veins
 Smoking










 Advanced age

Chronic heart failure
Thrombophilia
Prior history of VTE
Respiratory failure
Stroke
Cancer
Chemotherapy
Hormone replacement
therapy
 Pregnancy ‐ Postpartum

 Pregnancy ‐ Prepartum
 Laparoscopic surgery
 Central Venous Catheters

Based on this summary, risk factors are separated into three different groups i.e.
modifiable, non‐modifiable and temporary based on the nature of the factor. Some
factors such as age or thrombophilia are not changeable and once a patient
acquires them, they will always have them. Some factors on the other hand are
modifiable like smoking or obesity. These factors can be modified by patient
education and self‐care. The last group are the temporary factors. Factors like
cancer or pregnancy must take their due time to be resolved, and generally are out
of the hands of the patient to modify.
Caprini Risk Assessment Model
A number of risk assessment models have been published in attempt to stratify
patients based on their risk for venous thromboembolism. The most widely used of
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one was developed by Caprini, Cohen and Kucher in 2005 based on a combination
of clinical experiments and published data [21‐25].
The “Caprini Risk Assessment Model” includes a list of temporary factors such as
specific procedures or illnesses, and non‐modifiable factors such as genetic and
clinical characteristics, with assigned relative risk scores to each factor[22, 23].
Then individual risk scores are summed to create a single cumulative score. This
cumulative score is used to assign risk levels to individual patients. This helps
determines the type, intensity and duration of medical prophylaxis used for each
patient.
One example of a Caprini risk assessment questionnaire is shown in Figure 8. It
is maintained on the Agency for Healthcare Research and Quality (AHRQ) Website:

Figure 8 ‐ Caprini VTE Risk Assessment ‐ Sample Form 8

8

Agency for Healthcare Research and Quality (AHRQ) Website at https://www.ahrq.gov
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Table 4 shows how the total risk score is used to determine prophylaxis regimen
in a patient 18 or over who has no condition such as active bleeding that prevent
receiving medical prophylaxis. Based on this table, while Caprini score of zero or
one indicates low risk for getting a blood clot, ordering anticoagulation is not
necessary. On the other hand, as the Caprini score elevates, more potent
anticoagulations with higher concentrations are suggested to be ordered.

Table 4 ‐ Caprini Risk Score levels and Recommendations – Sample Table
Total Risk Factor Score

Incidence of DVT

Risk Level

Prophylaxis Regimen

0‐1

<10%

Low

No specific measures, Early ambulation

2

10‐20%

Moderate

ES. IPC, LDUH or LMWH

3

20‐40%

High

IPC, LDUH or LMWH

4

40‐60%

Highest

Pharmacological;

(1‐5% Mortality)

LDUH,

LMWH,

warfarin or Fxa inhibitor alone or in
combination with ES or IPC

ES/GCS= elastic stockings/graduated compression stockings; IPC= Intermittent pneumatic compressions;
LDUH= low‐dose unfractionated heparin; LMWH= low molecular weight heparin

Although the effectiveness of the Caprini risk assessment has been validated for
several different groups of patients[15], there has been criticism around its use.
First, it is found to be cumbersome to use, for it requires manual chart reviews and
patient examination thus, the model needs to be validated even more for
implementation in EHR[2, 26]. Second, the intercorrelation of individual risk factors
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is not factored into the model, Thirdly, the model puts most of the hospitalized
patients at the high‐risk group which increases the risk of administrating
unnecessary prophylaxis and putting them at risk of bleeding. For example, any
patient above age 60 and obese is automatically scored in the high‐risk group and
should receive prophylaxis. With Henry Ford Health System’s patient population,
this model would place almost 95% of the medical patients in the high‐risk groups.
The Caprini risk assessment model was not selected to be implemented in Henry
Ford’s EHR primarily because it requires manual intervention and has a large type
II error. In addition, the Caprini risk assessment model was designed based on
surgical patients; the aim of this research was to develop a real‐time risk
assessment model for mainly medical patients.
Padua Risk Assessment Model
In 2010, Barber et al published a prospective study of a cohort of 1,180 patients
admitted to a department of internal medicine that were classified at a low or high
risk for VTE over a two year period [27]. Cohort patients were followed up on for
up to 90 days to check for any occurrences of VTE. The main aim of the study was
to see if compliance to VTE prophylaxis in high and low risk patients made a
difference in getting a VTE in either of the patient groups. In this study, 39.7% of
the patients were marked as high‐risk patients. Patients in this group were five
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times more at risk of getting a VTE if they did not receive prophylaxis compared to
patients who received prophylaxis (11% vs. 2.2%). VTE was also reported in two
cases of low‐risk patients which accounted for 0.3% of entire low‐risk patient
population. Bleeding was also documented in three high‐risk patients which
translated to 1.6% of the patient population.
The proposed model was named “Padua Prediction Score” after the University
of Padua in Italy since all patients were selected from the Second Division of
Internal Medicine of the university’s hospital. As authors put it, “the model itself
was empirically generated by adding a few more variables to the Kucher’s model"
[25] and adjusting scores associated with each factor. Like the Caprini model,
individual scores from each factor are added up to create a single total Padua
Prediction Score. Any patient with a score of four or higher is considered at high
risk for getting a VTE.
Factors included in Padua are summarized in the below table, along with each
score assigned to each facto. For example, five features are each assigned scores
of 3. This alone would not warrant prophylaxis but adding any other feature such
as obesity or age over 70 would make the score 4 or higher.

Table 5 ‐ Padua Prediction Score Factors and Scores
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Baseline Feature

Score

Active Cancer

3

Previous Venous Thromboembolism(VTE)

3

Reduced Mobility

3

Already known thrombophilic condition

3

Recent (≤1 month trauma and/or surgery)

2

Elderly Age (≥70 years)

1

Heart and/or respiratory failure

1

Acute Myocardial Infarction (MI) and/or Ischemic Stroke

1

Acute infection and/or rheumatologic disorder

1

Obesity (BMI ≥30)

1

Ongoing hormonal treatment

1

Padua Prediction Score in Real‐Time and Challenges
The Padua risk assessment tool is designed for manual chart reviews and/or a
patient examinationOur challenge was to find pieces of information from the EHR
that can be used either directly or as a surrogate to replicate factors used in Padua.
We then needed to show that the modified model is effective. Below is the list of
Padua factors along with the challenges of translating each factor:
Active Cancer: In the Padua paper, Active Cancer is defined as “Patients with local
or distant metastases and/or in whom chemotherapy or radiotherapy had been
performed in the previous 6 months.”[27]
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Active Cancer is one of the most challenging factors to translate in the Padua
model. Based on the definition, there are two pieces of information that need to
be identified. Patients with local or distant metastases and chemo/radiotherapy.
Below is a description of challenges with each piece:
 Patients with local or distant metastases: Generally, there are two main
ways to find patient conditions like metastases: Laboratory/Imaging results
and H&P/Progress notes. In this case, imaging and lab results were not
usable since the results are stored as a free text field, and complicated text
analysis method would be needed to identify cancer. The same logic applied
to H&P and Progress notes because they also required complex text analysis.
There were two main problems to implementing text analysis. First, text
analysis proved to be very cumbersome and time consuming to setup and
optimize. Second, the EHR did not support the functionality to implement
such complex methods.
 Chemotherapy or radiotherapy had been performed in the previous 6
months: Chemotherapy and radiotherapy are usually done in outpatient
centers. An initial analysis identified the following challenges to use this as a
surrogate indicator of active cancer. The chemotherapy medication and
concentration combination were not than specific enough to pinpoint active
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cancer. There were also other reasons for receiving the medications or
radiotherapy. Therefore, the clinical staff advised the project not to use
these triggers to find active cancer patients.
The only remaining alternative was to use information from problem list charting
in the EHR and to develop a meaningful logic that would yield reasonably
meaningful and useful results. The first logic used was to use open problem list
items from patients’ records. Initially, to identify cancer among other items within
the problem list, a list of ICD99 codes were used. This initial list is available in the
appendix.
ICD9 was originally a three to five‐digit code that was designed mainly for billing
and tracking to specify patient diagnosis and problems. The model then was
extended in two different versions in the US (ICPM and ICD‐9‐CM) to include
procedure and diagnostic tests. In 1979, the US started requiring ICD‐9‐CM to pay
for Medicaid and Medicare claims. The structure of the ICD9 code is depicted in the
below figure.

9

9th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD), a
medical classification list by the World Health Organization (WHO)
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Figure 9 ‐ Structure of ICD910
Initial chart review for a group of 40 patients showed that none of the cancer
cases were missed. However, using problem lists triggered five cases with a history
of cancer but not active cancer. This revealed a general problem with using problem
lists. Interviewing a few physicians and reviewing charts of patients clarified that
providers were not as accurate in documenting resolution of patients’ problems
compared to noting a new problem. As explained in the beginning of this chapter,
although this causes data to inflate number of patients deemed to have active
cancer, it does not miss active cancer patients.
After working with the data for a few months and going through more sets of
chart reviews, the final list of ICD9 was limited to any ICD9 number starting with
140 through 209. This list proved to capture less false positives for the Padua risk
assessment tool while keeping its sensitivity to finding active cancer in the problem
list. One event that affected the study greatly was the introduction of the tenth
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version of the International Classification of Diseases (ICD10) in Oct 2015. The new
global coding system increased the number of codes to more than 14,000 and the
new challenge was to adjust criteria for each of the entries using the ICD10 list. The
new coding system uses a character followed by two digits that describes the
category of diseases, signs and symptoms, abnormal findings, complaints, social
circumstances, or external causes of injury or diseases.

Figure 10 ‐ Structure of ICD10 code11
For example, character “S” is used to identify a group of problems containing
injury, poisoning and certain other consequences of external causes. The next two
letters are then used to identify specific category of problems. In the below
example, S42 is used to indicate “Displaced Transverse Fracture.” The second half
of the code, which is separated from the first three letters using a dot, is used to
describe the problem more specifically. For problems and symptoms that do not
necessarily need a more specific description, this part is not mandatory.

11
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In the below example, the first digits i.e. 3, identifies the etiology of a fracture
identified as Humerus. The second digit specifies the location i.e. 2 for shaft of the
Humerus. The third digit specifies the laterality. Here, 1 for right arm. The last
character which is “A” shows that this case is an initial encounter for this specific
problem.

Figure 11 ‐ ICD10 structure explained using an example12
For the case of active cancer, ICD10 codes started with letter “C”. The full list is
available in the appendix.
Previous Venous Thromboembolism(VTE): In the Padua risk score, previous VTE is
one of the factors with three points. This factor is explained by Barber et al. as
“Previous VTE (with exclusion of superficial vein thrombosis)” and this is exactly the
criteria used in chapter one for VTE harm measurement. The major difference is all

12
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problem list including active encounter and previous encounters as well as medical
history of the patient must be considered.
One of the early challenges was to identify a list of ICD9 codes that indicate
presence of DVT or PE. Before October 2015 and when only ICD9s were available,
finding a clear distinction between deep vein thrombosis and superficial vein
thrombosis was impossible. In some instances, shared ICD9 codes had been defined
to identify both deep as well as superficial vein thrombosis. Hence, an initial set of
ICD9 codes were selected by sifting through the list of ICD9 codes with a provider.
The list then optimized through a few iterations of selection and chart reviews until
an acceptable final list was obtained. This final list of ICD9 codes is attached in the
appendix.
The introduction of the ICD10 codes in October 2015 required us again to update
the rules for identifying previous VTE. Over a few months’ time period and using
the same procedure, an initial list of ICD10s was transformed into a final list of
ICD10 codes to determine previous VTE. In each step, a set of chart reviews should
have been performed by physicians to determine if a (set of) ICD10 code should be
included/excluded. Then false positive and false negative rates were reviewed.
However, the major advantage of the ICD10 is its specificity of the coding system,
which helps determine a meaningful clean list of ICD10s representing VTEs.
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There are cases in which providers did not select a specific entry from the problem
list and simply wrote the VTE instance into the problem list. These cases are not
considered in the model due to the fact that EHR does not support implementation
of text search in the logic.
Reduced Mobility: Reduced mobility was another challenging factor in determining
the Padua risk score. It scored three points, making it important to identify it as
accurately as possible. In the Padua study, reduced mobility is described as
“Bedrest with bathroom privileges (either due to patient’s limitations or on
physician’s order) for at least 3 days.” by Barbar et al. [27]. Finding bedrest orders
from the EHR has its own challenges. Although bedrest orders are captured within
the EHR, they are generally not well‐documented and nor tracked very well. In the
case study, the end or stoppage of any order in the EHR was not reliably recorded.
As a result, and after meetings with different providers, it was decided not to use
bedrest orders to determine reduced mobility.
Different alternatives were identified and discussed. Eventually the only reliable
candidate, the “Braden Mobility Scale” was used as a surrogate to determine
reduced mobility. This scale is one of the components of the Braden tool that was
originally created in 1987 by Barbara Braden and Nancy to predict pressure ulcer
risk [28]. Below is a summary of different scales of the Braden mobility scale:
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1‐ COMPLETELY IMMOBILE – Does not make even slight changes in body or
extremity position without assistance.
2‐ VERY LIMITED – Makes occasional slight changes in body or extremity
position but unable to make frequent or significant changes independently.
3‐ SLIGHTLY LIMITED – Makes frequent though slight changes in body or
extremity position independently.
4‐ NO LIMITATIONS – Makes major and frequent changes in position without
assistance
One of the biggest advantages of Braden Mobility Scale is the availability of data.
Per nursing protocols, nurses are required to document this score every four hours,
every one hour, and every 30 minutes for patients in general units, intensive care
units, and patients with restraints respectively. Not only is this scale well
documented, and readily available as an integer data field, it is also reasonably
accurate.
However, one major problem with using this scale is the principle that
determination of the reduced mobility must be called by the providers while in real
time, the scale is determined and documented by nurses. At first, the validity of the
criteria was questioned by a few providers. However, , they eventually agreed that
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the use of the Braden scale is logical and in in fact the best surrogate alternative
available in the EHR.
The challenge following this was to determine the correct level of the Braden
Mobility Scale that could determine or imply reduced mobility. A patient with a four
was obviously not immobile. The problem was to draw a line to determine the right
level within the scale from 1 to 3. A one was probably the most obvious to include
in the criteria. Initial data analysis shows that only a small percentage of the
patients were given a score of one. At the same time, scale three was extremely
general. An initial data analysis showed that most hospitalized patients regardless
of condition, faced this level of reduced mobility at some point.
Eventually scale one and two were considered as surrogates to determine
reduced mobility for the risk of VTE. Note that the Padua study described the
reduced mobility to be somewhat lengthy (three days). However, using one data
point seemed acceptable since it reduces the potential chance of missing patients,
ultimately reducing the type I error.
Already Known Thrombophilic Condition: Defined as “Carriage of defects of
antithrombin, protein C or S, factor V Leiden, G20210A prothrombin mutation,
antiphospholipid syndrome”[27].
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The description simplifies the determination of thrombophilia, since there are
different problems that can cause temporary thrombophilic conditions. The
description clearly specifies only congenital and genetically carried conditions.
Like cancer and VTE history, a problem list was used to determine thrombophilia.
Initially “ICD9 287.5 Thrombocytopenia, unspecified” was used in the logic. After
October 2015 “ICD10 D69.6 Thrombocytopenia, unspecified” was used as the
criteria to find thrombophilia.
Recent (within last month) Trauma and/or Surgery: This factor is the only one
within the Padua score that gets two points. Unfortunately, there is no specific
description of this factor in the Padua study, and the description of “trauma” can
have many different definitions. Therefore, defining “trauma” was one of the
primary challenges for this factor. Luckily, Epic EHR had an internally predefined set
of diagnosis lists that was used to determine and define trauma. By the beginning
of 2017, there were more than 1.6 million entries on this list, preventing it from
being reported in this document. The major advantage of this set is the fact that
the EHR itself (in this case a team in Epic), oversees making sure the list is being
maintained and updated. Therefore, there was no need to develop or maintain a
list of all trauma diagnosis codes. Many chart reviews with providers proved that
the predefined set is performing reasonably well. As a result, the problem list along
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with notation date of the problem list entry (which must have happened within 30
days prior to the assessment time) were used as the criteria to determine “recent”
trauma.
Catching recent surgery within 30 days was far easier to identify as surgical cases
are well documented within the surgical module in the EHR. The major problem
with identifying either recent trauma or surgery within 30 days, is the fact that any
prior medical condition or surgery is documented in the medical history and
surgical history of the patient. However, neither of them have specific date fields
to capture occurrence date and time. The date and time is rather captured within
a text field, and as a result, it is not reliably and correctly identifiable. Therefore,
any instance of recent surgery or trauma if served and recorded within another
health system is potentially missed using this method. The proposed model would
miss these cases.
Elderly age (Greater or equal to 70 years): While the age factor only gets one point
within the Padua score, it is the most straightforward factor to identify. Age of the
patients at the time of assessment (which is current system time) is considered to
determine age and if the patient is 70 years of age or older, they are assigned one
point.
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Obesity (BMI Greater or equal to 30): Obesity is reasonably straightforward to
identify. A patients’ BMI is normally calculated at any time using the last measured
(known) patient height and weight. In this case, patients who have a BMI of 30 or
greater, are assigned one point.
Heart and/or Respiratory Failure: Having a history of either heart or respiratory
failure gets one point in the Padua risk tool. Fortunately, like trauma, there is a
predefined set of diagnosis codes used to determine them. These sets were utilized
in both medical history of patients and their problem lists to determine history of
heart or respiratory failure.
Acute Myocardial Infarction (AMI) or Ischemic Stroke: As with heart and
respiratory failure, there were predefined sets available for both AMI and ischemic
stroke. The same process was followed for this factor and any patient with a history
of AMI and/or ischemic stroke was assigned one point.
Acute Infection and/or Rheumatologic Disorder: Based on this factor, any patient
with rheumatologic disorder and/or acute infection should get one point in the
Padua risk assessment tool. Rheumatologic disorder could be identified using the
problem list and medical history of the patient. The final list of ICD9 and ICD10 that
was used respectively prior to and after October 2015, is available in appendix.
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However, identifying acute infection proved to be much harder than initially
thought. Unfortunately, there was no easy way to capture it. One difficulty in
finding acute infections was the fact that patients must have the condition at the
time of the assessment to receive the additional point. Again, using H&P to capture
acute infections was out of the question since it required natural language
processing. Problem lists also proved to create a huge number of false positives.
To overcome this issue, an algorithm was developed to identify acute infections
more accurately. The idea for the algorithm came from the VTE harm measurement
that was explained in chapter one. In theory, a patient should have had an acute
infection if they had an entry for any type of infection in their problem list and
receiving any type of anti‐bacterial, anti‐viral or anti‐fungal treatment. A series of
50 initial chart reviews showed that the algorithm performs reasonably well. While
the proposed algorithm enjoyed a sensitivity of 100%, it generated five false
positives.
Fortunately, building the proposed algorithm did not require perfection of a long
list of ICD9/ICD10s and infection medication treatments. Because Epic EHR also
included a predefined set of infection diagnosis codes as well as a list of infection
treatment medications.
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Ongoing Hormonal Treatment: Ongoing hormonal therapy is another factor in the
Padua risk tool that can get up to one point. There were two main reasons that
made identification of ongoing hormonal treatment a challenge. First, determining
the “ongoing” part of the factor was not possible. Therefore, it was decided to look
at patients with any type of hormonal treatment. And second, the EHR did not
provide a predefined list of entire hormonal treatment medications, and
developing a clean list of medications that can be counted as hormonal treatment
was not a trivial task. There were literally thousands of medications that could be
counted in the list, and cleaning the list seemed impossible. And with new
medications being added by the pharmacy on a regular basis, maintaining the list
was impossible.
The only option was to use one of the predefined list of medications in the EHR,
which only included a portion of the medications. However, it was maintained by
the EHR on a regular basis.
Performing a few chart reviews with the physicians showed using this predefined
list can miss a fair amount of true cases of hormonal treatment. Several discussions
with physicians did not produce a better alternative to improve the logic and hence,
it was decided to use the predefined list in the final design.
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Padua Risk Assessment ‐ Implementation
The implementation of the tool in the EHR took about 6 months to complete and
perfect. EHR tools for deploying risk assessment tools have limitations and nuances
that needed to be investigated. Basically, on each iteration of updating the tool in
the EHR, the results had to be compared to the ones from the program to make
sure the deployed tool reflected accurate results based on intended designs.
The figure below shows how the tool can be utilized by the providers on their
day to day job. There are two ways to show the Padua risk score in the EHR. Either
physicians can add the score to their assigned patients’ lists, or they can run a
report that lists every single patient in the hospital along with the risk scores.
Figure below is a real example of a few patients that were admitted to the ICU
at Henry Ford Hospital on a specific date and time. Patient identifiers are covered
with black ink to ensure privacy of the patients.
It is worth noting that the Padua score is measured for each patient on the fly,
and as soon as anything occurs that could change the score, the records are
updated in real time. Scores of four or greater which represent high‐risk patients
are clearly marked in red to stand out.
One powerful aspect of this tool is that providers can add the risk score side by
side with heparin/LMWH and/or anticoagulation medications. In this case, they can
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quickly go through their lists of patients and investigate whether a high‐risk patient
is receiving prophylaxis, if they have a contraindication to receive one, or if they
must order VTE prophylaxis for the patients. They can also find patients with low
risk of VTE and decide if they need to stop the VTE prophylaxis for them.

Figure 12 ‐ Patient List within EHR showing Padua Risk Score
In the above example, the first patient is clearly at risk of VTE with a Padua score
of eight. And the next two columns indicate that they are not receiving any
anticoagulation. The next step for the providers is to investigate if there is a
contraindication for not receiving anticoagulation. In this example, the patient
clearly has a problem of “Acute Upper Gastrointestinal Bleeding” as their primary
problem, and that is one major reason not to receive blood thinners.
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This tool also provides another functionality. The fifth patient on the list shows
a very high Padua risk score of 11. The patient is not receiving any anticoagulation,
and the main problem on the list does not provide any insight as to whether there
are contraindications for not receiving prophylaxis. In cases like these, providers
should open patients’ charts and review their records. This can take some time.
The drawer tool within the Padua tool makes this task much easier. There is a
button on the bottom of the providers’ list that provides a summary of patient
records. This helps providers quickly review a long list of patients in a short amount
of time. In this example, the provider can quickly identify that the patient has active
cancer, reduced mobility and a history of congenital heart failure.
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Figure 13 ‐ Drawer Tool Showing Details within Padua Tool in EHR
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Padua Risk Assessment – Accuracy and Effectiveness
The below table summarizes the number and percent of patients identified as
high risk for developing VTE. The analysis is done separately for medical patients
from specific medical units within Henry Ford Hospital, as well for all patients within
the health system.
The data shows that Padua risk assessment only identifies 25% of the medical
patients as high risk for developing a VTE (23% for all patients). This shows higher
levels of sensitivity compared to the Caprini model. Initial estimates for the portion
of patients considered to be high risk with the Caprini model were above 90%. Our
new scale eliminated unnecessary prophylaxing of roughly 64% of the patients,
which in turn reduces their risk of developing internal bleeding.
Table 6 ‐ Ratio of High Risk Patients using Padua Risk Score
Patient Group
Medical Patients within
specific units within HFH
All Patients within system

Low Risk VTE
(Population and %)

High Risk VTE
(Population and %)

Total

10,685 (63.5%)

6,132 (36.5%)

16,817

165,074(66.2%)

84,248(33.8%)

249,322

Table below shows how the Padua risk score performs as a predictive of
developing VTE. To sum up, the rate of developing a VTE among low risk medical
patients was only 0.34%, compared to 2.33% for high risk medical patients. Looking
at all patients within the health system the same ratio is 0.28% compared to 2.33%.
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Table 7 ‐ VTE Harm Rate in High Risk and Low Risk Patients
Patient Group

Medical Patients within
specific units within HFH
All Patients within system

Low Risk VTE
(Number and VTE%)

High Risk VTE
(Number and
VTE%)

Total

12,605 (0.34%)

4,212 (2.33%)

16,817(1.06%)

190,986(0.28%)

58,336(2.33%)

249,322(0.98%)

Performing a t‐test for comparison of proportions in the two groups using alpha=
0.05 concludes that there is significant difference between the VTE harm rate in
each group.

Figure 14 ‐ t‐Test output for difference of VTE rates
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Figure 15 ‐ Confidence Intervals for comparison of VTE Harm Rates
This Padua EHR implementation proved to be very useful. However, this chapter
identified and discussed its shortcomings. The next chapters explain an alternative
risk assessment model improves the performance of the model. Chapter 5
summarizes the outcome of the Padua model and the contributions it made to
hospital quality and patient safety.
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CHAPTER 4 ALTERNATIVE TO PADUA – IMPROVE
In this chapter, another well‐known VTE risk assessment model ‐ “IMPROVE”‐
will be discussed. This will include a review of the validation of the performance of
this model will be reviewed. Finally, a comparison between IMPROVE and the
implemented Padua risk assessment model in the EHR will be provided.
Why IMPROVE?
In the previous chapters, the Padua risk assessment model and its advantages
were discussed; however, there are some challenges when it comes to the
implementation of this model which motivated the review and introduction of
another VTE risk assessment model in this chapter. The implementation challenges
of the Padua model are as follows:
 To implement the Padua model, some trade‐offs were needed to be made
(such as using the Braden score as a surrogate indicator for determining
immobility) which have been discussed in the previous chapters. These
trade‐offs could potentially have an adverse effect on the performance of
the Padua model in terms of its sensitivity and specificity. Furthermore, a
few physicians were reluctant to use the model due to these trade‐offs
and the complex explanations that come with them.

63
 In general, the Padua is a complicated model, and not every physician can
quite understand the relationships in the model. They also tend to
question the underlying structure of the implemented model. Explaining
the complex implementation concepts seem to overwhelm and
sometimes confuse some physicians.
 There is no consensus between experts with regards to the accuracy and
performance of this model.
 Design and implementation of the Padua model is complicated due to the
number of parameters used. It is, therefore, difficult to timely and
accurately trace the important changes in these parameters over time.
This can make the maintenance of the Padua model quite burdensome,
time consuming, and in some ways, impossible. Not only can this
negatively affect the performance of the model, but also the physicians’
perception of it.
IMPROVE Risk Assessment Model
Spyropoulos, MD et al. introduced the IMPROVE risk assessment model in their
paper titled “Predictive and Associative Models to Identify Hospitalized Medical
patients at Risk for VTE” in 2011 [29]. The model was derived through multiple
regression analysis of more than fifteen thousand hospital admissions that were
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observed for a period of three months after discharge. All data was obtained from
the observational International Medical Prevention Registry on Venous
Thromboembolism (IMPROVE) study.
Spyropoulos, MD et al. concluded their study with a weighted VTE risk score
using only four clinical factors. The table below summarizes these factors along
with the reported significances and points assigned to each factor in the model[29]:

Table 8 ‐ Adjusted Predictive Model for VTE – Improve Model[29]
VTE Risk Factor
HR (95% CI)
Χ2
P Value
Points
Previous VTE
5.0 (3.3‐7.8)
53
<0.001
3
Known Thrombophilia*
5.2 (1.3‐21.5)
5.2
0.02
3
Cancer
2.0 (1.3‐3.1)
11
0.001
1
Age > 60 y
1.8 (1.2‐2.7)
8.5
0.004
1
* Antithrombin, protein C, protein S, factor V Leiden, prothrombin gene mutation, or
antiphospholipid syndrome[29].

In this model, the total risk score is calculated by adding all the points from each
factor, and a total score of two or more is considered as a high risk for VTE.
Validation of the IMPROVE Model– Literature Review
There have been a few studies that aimed to validate the IMPROVE risk
assessment model. For instance, assessing the validity of the model was the main
subject of a study published in Journal of the American Heart Association (JAHA) by
Rosenberg et al. in 2014[30]. This study reported an overall VTE rate of 0.7% for a
population of 19,217 patients who matched the criteria of the IMPROVE study.
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They observed a 0.42% (95% CI 0.31 to 0.53) rate for low risk patients, and 1.29%
(95% CI 1.01 to 1.57) rate for high risk patients as identified by IMPROVE risk
assessment model.
The paper titled “External validation of a risk assessment model for venous
thromboembolism in the hospitalized acutely‐ill medical patient (VTE‐VALOURR)”
published by Mahan et al.[31] also sought validation of the IMPROVE model. Using
a cohort of 41,486 hospitalizations, VTE rates of 0.20% (95% CI 0.18 to 0.22), 1.04%
(95% CI 0.88 to 1.25) and 4.15% (95% CI 2.79 to 8.12) were reported for low‐risk,
medium‐risk and high‐risk VTE patients respectively. In this study, 68.6%, 24.8%
and 6.5% of the patient population were classified by the IMPROVE model as low‐
risk, medium‐risk and high‐risk patients. Area Under Curve(AUC) was also found to
be 0.7731 for IMPROVE risk assessment model.
Lew et al. (2017) published the paper “Extended‐duration versus short‐duration
pharmacological thromboprophylaxis in acutely ill hospitalized medical patients: a
systematic review and meta‐analysis of randomized controlled trials”[32]. They
concluded that extended duration thromboprophylaxis administration for high risk
VTE patients as identified by IMPROVE model

reduces the overall risk of

symptomatic DVT and symptomatic non‐fatal PE with increase in risk for major non‐
fatal bleeding [32].
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IMPROVE Risk Assessment Model – EHR Implementation Analysis
Implementation of any new model in the EHR must undergo feasibility studies
and IMPROVE was no exception. However, performing the feasibility studies for
IMPROVE was straightforward. As the IMPROVE model consists of only four main
factors (i.e. previous VTE, thrombophilia, active cancer and age older than 60 years)
which are among factors that were used in developing the PADUA model.
Therefore, all four factors could be copied from the existing build to create the new
IMPROVE model.
Our initial analysis was designed to see how IMPROVE performed against the
currently developed PADUA model. First, there was a determination of the
percentage of medical patients that are considered high risk for VTE. These are the
patients that will get medical VTE prophylaxis. Initially four specific units were
considered to do this analysis. These units are “HFH B1 Internal Medicine,”, “HFH
B4 Internal Medicine,” “HFH F1 Hospitalist Medicine,” and “HFH F4 Internal
Medicine”. These units were selected from Henry Ford Hospital because they are
serving similar medical patients who do not have major complications that could
potentially affect the performance of either models.
Among 16,817 patients who visited any of these four specific units since January
2014 until April 2017, PADUA identified 6,132 (36.46%: 95% CI 35.45% to 37.47%)
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as high risk and 10,685 (63.54%: 95% CI 62.77% to 64.31%) as low‐risk VTE patients.
For the same group of patients IMPROVE identified 4,212 (25.05%: 95% CI 23.95%
to 26.15%) and 12,605(74.95%: 95% CI 74.32% to 75.58%) respectively as high‐risk
and low‐risk VTE patients. Table below summarizes this comparison.
Table 9 ‐ Patient Population: PADUA vs. IMPROVE
Assessment Model
Implemented PADUA
IMPROVE

Low‐Risk VTE Patient Count (%)
10,685 (63.54%)
12,605 (74.95%)

High‐Risk VTE Patient Count (%)
6,132 (36.46%)
4,212 (25.05%)

Figure 16 and Figure 17 show the results of t‐tests used to check the statistical
significance of differences between proportions using two methods. These tests
conclude that IMPROVE significantly marks less patients as high‐risk compared to
PADUA. Conversely, IMPROVE identifies more patients as low‐risk compared to
PADUA. To put this into perspective, PADUA on average puts almost 11 more
patients out of any 100 patients on medical prophylaxis compared to IMPROVE. As
discussed, in addition to direct costs of medical prophylaxis for 11 patients, this
means 11 more patients at risk of internal bleeding.

68

Figure 16 ‐ High‐Risk VTE Patient Proportion Test: PADUA vs. IMPROVE

Figure 17 ‐ Low‐Risk VTE Patient Proportion Test: PADUA vs. IMPROVE

The study next compared how these models perform in determining risk of
getting a VTE. Analyzing the same group of patients, 0.34% (95% CI: 0.25% to
0.43%) of them were identified as low‐risk for VTE by PADUA acquired a VTE, while
2.33% (95% CI: 2.01% to 2.65%) of high‐risk VTE patients acquired a VTE. IMPROVE
outperformed PADUA. Only 0.28% (95% CI: 0.2% to 0.36%) of low‐risk patients
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experienced a VTE as compared to 3.42% (95% CI: 2.96% to 3.88%) for patients
identified as high‐risk VTE. This comparison is summarized in table below.

Table 10 ‐ PADUA vs. IMPROVE: VTE Rate Comparison
Assessment Model
Implemented PADUA
IMPROVE

Low‐Risk: VTE Rate (%)
0.34%
0.28%

High‐Risk: VTE Rate (%)
2.33%
3.42%

The below figures show t‐test results for comparing VTE rates in each group. To
summarize, patients who were identified by IMRPOVE as high‐risk were
significantly more likely to experience a VTE than patients who were identified by
PADUA as high‐risk. In low‐risk patients, although the results were not statistically
significant, IMPROVE identified low‐risk patients had a lower VTE rate.
These analyses show that IMPROVE can significantly reduce the cost and need
for prophylaxis, thereby reducing the risk of bleeding. It also was significantly more
sensitive in identifying patients who are truly at risk of VTE.
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Figure 18 ‐ VTE Rate in Low‐Risk Patients t‐test: PADUA vs. IMPROVE

Figure 19 ‐ VTE Rate in High‐Risk Patients t‐test: PADUA vs. IMPROVE
The above analysis was first performed for a group of similar patients who did
not have complexities that could affect the model. But what if the same analysis is
done for all patients including GI bleed, stroke, surgical patients, and so on? The
same analysis was performed using a dataset of nearly 250,000 hospital admissions
across four different hospitals since January 2014.
Data analysis on the new more diverse and larger group of patients virtually
showed the same results. Out of 249,322 patients 165,074 (66.21%: 95% CI 66.02%
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to 66.40%) and 84,248 (33.79%: 95% CI 33.52% to 34.06%) were identified as low‐
risk and high‐risk VTE patients using implemented PADUA model. The
corresponding statistics for IMPROVE model are respectively 190,986 (76.6%: 95%
CI 76.44% to 76.76%) and 58,336 (23.40%: 95% CI 23.11% to 23.69%) for low‐risk
and hi‐risk patients.
Below is a summary of these results as well as statistical analysis for difference
between proportions. These results confirm previous analysis and show that
IMPROVE will, on average, result in 10% fewer high‐risk patients compared with
PADUA. In this study, this is a total of almost 26,000 fewer patients needing
prophylaxis.
Table 11 ‐ Patient Population: PADUA vs. IMPROVE
Assessment Model
Implemented PADUA
IMPROVE

Low‐Risk VTE Patient Count (%)
165,074 (66.21%)
190,986 (76.60%)

High‐Risk VTE Patient Count (%)
84,248 (33.79%)
58,336 (23.40%)
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Figure 20 ‐ Low‐Risk VTE Patient Proportion Test: PADUA vs. IMPROVE

Figure 21 ‐ High‐Risk VTE Patient Proportion Test: PADUA vs. IMPROVE
In terms of VTE rates, IMPROVE still outperforms PADUA in sensitivity for
determining high‐risk patients. VTE rates for low‐risk patients are virtually the same
with 0.28% for PADUA compared with 0.29% for IMPROVE. On the other hand,
IMPROVE had a rate of 3.24% VTE for its high‐risk patients compared with 2.33%
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for high‐risk patients identified by PADUA. These rates along with statistical analysis
comparing two groups together are summarized below.
Table 12 ‐ PADUA vs. IMPROVE: VTE Rate Comparison
Assessment Model
Implemented PADUA
IMPROVE

Low‐Risk: VTE Rate (%)
0.28%
0.29%

High‐Risk: VTE Rate (%)
2.33%
3.24%

Figure 22 ‐ VTE Rate in High‐Risk Patients t‐test: PADUA vs. IMPROVE

Figure 23 ‐ VTE Rate in Low‐Risk Patients t‐test: PADUA vs. IMPROVE
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IMPROVE Implementation Assessment – Enhancement
The second step in designing the IMPROVE model for implementation in the EHR
was to specify factors that could be better identified by extracting information from
the EHR. Age is a factor that could not be improved. For the other three factors,
active cancer was the most challenging one. These challenges were explained in
chapter three. To summarize, active cancer is determined by considering open
entries in problem list that have any of the identified cancer ICD10 codes.
A cancer code on the problem list does not necessarily mean the cancer is active.
It is considered active cancer if the cancer problem was added or updated within
the current hospital encounter. Thus, if a patient is admitted to the hospital and
the admitting physician does not document the active cancer in the problem list,
this cancer is not included in the risk factor.
The new improved model hereafter is called “Enhanced IMPROVE”. Below is a
summary of how the new design lines up against the other two models using the
controlled group patients and bigger patient group.
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Table 13 ‐ Low‐Risk and High‐Risk Patient Population ‐ Enhanced IMPROVE
Sample

Assessment Model

Four Units

All Four
Hospitals

Implemented PADUA
IMPROVE
Enhanced IMPROVE
Implemented PADUA
IMPROVE
Enhanced IMPROVE

Low‐Risk VTE Patient
Count (%)
10,685 (63.54%)
12,605 (74.95%)
13,394 (79.65%)
165,074 (66.21%)
190,986 (76.60%)
203,889 (81.78%)

High‐Risk VTE Patient
Count (%)
6,132 (36.46%)
4,212 (25.05%)
3,423 (20.33%)
84,248 (33.79%)
58,336 (23.40%)
45,433 (18.22%)

Table 14 ‐ VTE Rate ‐ Enhanced IMPROVE vs. PADUA vs. IMPROVE
Sample
Four Units

All Four
Hospitals

Assessment Model
Implemented PADUA
IMPROVE
Enhanced IMPROVE
Implemented PADUA
IMPROVE
Enhanced IMPROVE

Low‐Risk VTE Patient
Count (%)
0.34%
0.28%
0.28%
0.28%
0.29%
0.29%

High‐Risk VTE Patient
Count (%)
2.33%
3.42%
4.15%
2.33%
3.24%
4.06%

Both of the above tables show that Enhanced IMPROVE outperforms IMPROVE
and PADUA in terms of sensitivity and specificity. It reduced the number of patients
classified as high risk and those patients had higher rates of VTE. The increase in
low risk patients did not affect the rate of VTE within this group as compared to
IMPROVE.
The below graphs show statistical analysis performed comparing the Enhanced
IMPROVE and IMPROVE on these measures.
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Figure 24 ‐ High‐Risk Patient Population: IMPROVE vs Enhanced IMPROVE

Figure 25 ‐ Low‐Risk Patient Population: IMPROVE vs Enhanced IMPROVE
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Figure 26 ‐ VTE Rate in High‐Risk Patients: IMPROVE vs. Enhanced IMPROVE
Enhanced IMPROVE on average classifies 5% fewer high‐risk patients compared
to IMPROVE without increasing the aggregate risk of VTE for low‐risk patients. The
rate of VTE among high‐risk patients identified by improved IMRPOVE is also
significantly higher than IMPROVE with 4.06% which is the equivalent of one out of
every twenty‐five patients.
The risk of VTE for patient who identified as high‐risk by IMPROVE and low‐risk
by enhanced improve is calculated to be 0.32% for all patients in all four hospitals.
This is not statistically significantly higher than of 0.32% for Enhanced Improve
(using alpha=0.05).
Based on this analysis, “Enhanced IMPROVE” was selected and scheduled to be
implemented in late 2017‐ early 2018 into the EHR. It will then be used in all four
hospitals to determine VTE risk for patients and hence the VTE prophylaxis
regimen.
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The next chapter will explain outcomes of the developed PADUA model,
byproducts of this study, including data marts and dashboards, a few quality
projects and their outcomes that were performed using this study, and finally a
summary of a few publications that was made possible because of this study.
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CHAPTER 5 CONCLUSION: STUDY CONTRIBUTIONS AND RESULTS
This chapter discusses how this research contributes to improvements in
monitoring hospital acquired VTEs, an important hospital quality measure.
Furthermore, the discussion includes how the research leads to facilitating better
VTE risk management, and saving lives through targeted education of patients,
nurses and residents. The chapter then follows with discussions around how the
developed models have improved quality of patients’ lives and financial savings for
the hospital.
New Way of Hospital Acquired VTE Measurement
As discussed before, the traditional VTE measurement method uses billing data.
The drawbacks of this method included first, the lag between the time a VTE
episode occurs and the time it appears in the billing data, and second, this method
could not be easily linked to care. The new VTE measurement method proposed in
this research not only provides timely reports, but also assigns the VTE case to a
physician who can use this information to improve patient care.
The new VTE measurement method has been utilized in two different ways in
Henry Ford Health System since January 2014. First, a dashboard was created to
report VTE rates on a daily basis. Thus, physicians and hospital quality staff can use
this dashboard to monitor VTE rates in a timely manner. This near real‐time view
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of the VTE rates and VTE instances in the hospital enables them to intervene earlier
should there be even a small increase in VTE rates in a specific hospital or unit.
Second, a list of all the instances of VTE harm patients is sent to the specialty
division heads on a routine basis. Access to this data has enabled them to follow up
with specific physicians who have had a higher VTE rate compared to their peers or
the general physician group within the system. Moreover, since Henry Ford
Hospital is a large teaching hospital, these tools have enabled the physicians to
provide timely case specific feedback to residents which enhances education
opportunities. Since these cases are fresh and the patients are generally still
hospitalized, physicians can effectively review them with their residents and make
sure proper care procedures are followed.
The graph below shows a screenshot of the three‐month moving average for VTE
harm rates in all four main Henry Ford Health System’s hospitals. As depicted
below, the VTE rate system‐wide has decreased from around 1.1% to roughly 0.85%
over 2 years’ time.
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Figure 27 ‐ VTE Harm Dashboard ‐ Showing VTE trends by hospital
Table 15 shows VTE rates by hospital. Total system VTE rates for 2014 and 2015
were 1.09% vs. 0.85% since 2016. The difference is statistically significant using
alpha 0.05 with P‐Value = 0.0493.
Table 15 ‐ VTE rate by hospital and year

2014
2015
2016
2017 (Q1)

HFH
1.35%
1.25%
1.00%
1.13%

HFMH
0.93%
0.71%
0.68%
0.47%

HWFB
1.09%
1.31%
0.93%
0.72%

HFWH
0.82%
0.82%
0.65%
0.70%

SYSTEM
1.13%
1.06%
0.85%
0.85%

The decrease in VTE harm is equivalent, on average, to 180 less episodes of
hospital acquired VTE annually across the Henry Ford System. Based on studies that
suggest 30% of VTE hospital acquired patients suffer mortality within 30 days[33],
this decrease is equivalent to 54 lives saved annually. Furthermore, the Institute of
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Medicine (IOM) reported that one fifth of the surviving VTE patients experience
life‐long problems. These include recurrent VTE, post‐thrombotic syndrome (PTS),
and chronic thromboembolic pulmonary hypertension (CTEPH). This means that
the new method can save tens of patients each year from these recurring problems.
Using the 2013 data, the Agency for Healthcare Research and Quality (AHRQ) has
estimated that every instance of hospital acquired VTE will cost an additional
$8,000 for the hospitals to treat13. Considering that hospitals must absorb this cost,
the 180 less instances of hospital acquired VTE could mean $1.44 million in savings
for the health system. The IOM also reported an additional $14,000 to $17,000 cost
for the health plan for each instance of VTE. This suggests that Henry Ford Health
System could have saved more than $3 million annually just by decreasing the VTE
incidents.
As mentioned before, this study has enabled and supported numerous
improvement projects related to VTE across the Henry Ford Health System. Two of
the most important projects are trials that were done in HFH and HFWB:
First trial – Henry Ford Hospital
In addition to providing a timely dashboard, this study has supported and
enabled two specific trials in Henry Ford Hospital and Henry Ford West Bloomfield

13

https://www.ahrq.gov/professionals/quality‐patient‐safety/pfp/hacrate2013.html
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Hospital to decrease VTE harm rates among medically ill patients. The first adoption
of the model took place at Henry Ford Hospital. This trial was led by one of the
senior internal medicine physicians who realized the value of using the new model
and what it had to offer. Having the support of the hospital quality team, he led the
trial using the developed model. The efforts were focused around two main areas:
resident education and patient education.
‐ Resident education: The senior doctor reviewed all the instances of VTE with
his residents in four main medical units to ensure proper medical practices
were followed. In addition, every inpatient in those medical floors were
reviewed on daily rounds using the Padua model developed in the EHR to
ensure at‐risk patients either receive medical prophylaxis or have
contraindications to receive one.
‐ Patient education: Patients may miss or refuse their medical VTE prophylaxis.
This can be because some patients tend to generally avoid any medications
unless necessary for them. Also, the Subcutaneous (sub‐q) injection of the
prophylactic heparin is not very pleasant for the patient. To reduce these
instances, a patient brochure was designed to educate patients on VTE and
its risks. The benefits and risks of receiving medical prophylaxis were
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explained in the brochure. The idea behind designing this brochure is to
encourage patients to ensure they receive their medical prophylaxis.
‐ Below is a copy of this brochure that was designed and used in HFH.

Figure 28 ‐ Patient Education Brochure used at HFH (Front)
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Figure 29 ‐ Patient Education Brochure used at HFH (Back)
The graph below shows how the initiatives backed up by the proposed model
contributed to a decrease in the VTE rates in the selected units. VTE rates decreased
from approximately 1.6% to roughly 0.8% over a 2‐year period.
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HFH: Hospital Acquired VTE rate: B1, B4, F1 & F4 Units
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Figure 30 ‐ VTE rates in four main medical units in HFH
Second trial – Henry Ford West Bloomfield Hospital
Following the positive outcomes from the trial in Henry Ford Hospital, Henry
Ford West Bloomfield Hospital (HFWB) started an improvement project to reduce
VTE rates among their medically ill patients. The main medical units were once
again targeted, and potential areas for improvement were discussed. One of the
topics that was tackled was adherence to medical prophylaxis. Earlier, this study
proved that patients who miss at least one dose of prophylaxis are in a significantly
higher risk to get VTEs (Alpha = 0.05 and P‐Value < 0.0001). Therefore, the efforts
were focused around making sure that all patients receive their medical
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prophylaxis when they are ordered one. These efforts were focused on nurses and
patients alike.
Table 16 ‐ Prophylaxis Missed and effects on VTE Harm

‐ Nurse education: A medical prophylaxis report was sent to the group on a
regular basis to review medication administration and follow up with nurses
to ensure patients receive their medical/mechanical prophylaxis.
‐ Patient Education: A new brochure was designed using the previously
designed brochure at HFH. Further efforts were made to ensure that not only
patients receive the brochure, but they also read it to understand the risks
of VTE.
The graphs below depict the results of these efforts. Patient refusals of medical
VTE prophylaxis were reduced by two‐thirds from 15% to nearly 5%. In addition,
missing those medications for any other reason dropped from 25% to around 11%.
These decreases happened over a two‐year period.
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VTE Prophylaxis (chemical) ‐ Patient Refusals
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Figure 31 ‐ Patient VTE medical prophylaxis refusals at HFWB
VTE Prophylaxis (chemical) ‐ Missed Doses
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Figure 32 ‐ Patient VTE medical prophylaxis Misses at HFWB
Looking at the raw numbers of VTE instances at HFWB hospital, it shows that VTE
instances decreased by more than half in the same time period. Looking at the
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patient population in these units, the VTE rates dropped from approximately 1.3%
to nearly 0.6%.
Raw Number of VTE (blood clots) by quarter
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Figure 33 ‐ Quarterly VTE instances in HFWB medical units

VTE Datamart
As part of this study and to support the quality improvement initiatives related
to VTEs, a set of VTE data repositories called data marts were developed to perform
required retrospective data analysis for designing the VTE risk assessment models.
These data marts are updated daily, and currently include more than 270,000
inpatient encounters. The main VTE data mart contains more than 100 variables
and captures information such as patient identifiers, patient demographic data,
encounter‐specific identifiers, and medical characteristics of the patients. These
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medical characteristics are mainly designed and obtained to support the
development of the Padua risk assessment model. Therefore, all the factors used
in the Padua model are captured within the VTE data mart. Along with total
prophylaxis and treatments received, missed or refused, the data mart identifies
the first physician who ordered the prophylaxis. The system captures the dates
compression devices were ordered for the first time as well as the first and last time
a nurse documented their use on the patients.
The number of VTE imaging studies done on each patient are also captured
including CT chest scans, VQ lung scans, venous Doppler and duplexes. The system
also captures Gastrointestinal bleeding problem within the same encounter, and
whether the patient is thrombocytopenic.
Two other fields of the data mart are assigned to identify IVC filters using
placement orders and problem list. The next six fields are assigned to identify if the
patient has any types of lines including peripherally inserted central lines (PICC),
central venous catheter (CVC), midline catheter, dialysis catheter, implanted ports
and tunneled catheter lines. The total minutes that the patient spends in the
emergency department, operating room and under surgery are also included in the
data mart. This is followed by an identifier to indicate if the patient was later
readmitted to the hospital within 30 days.
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There are two data marts developed around VTE medication administration. One
of the lists contains every single administration order of any VTE prophylaxis,
including the name and type of the drug, time of administration, order frequency
and dosage, who ordered the medication, and what happened to the order. The
last data mart is basically the same but contains data on VTE treatment medication.
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CHAPTER 6 FUTURE RESEARCH OPPORTUNITIES
This chapter discusses a couple of areas of opportunity for future research.
VTE Harm Measurement
‐ Performing more chart reviews and identifying the status of VTE on an
inpatient stay. Capturing the time when VTE identified, physician assignment and
other nuances such as prophylaxis contraindications, reasons why patients did not
receive prophylaxis including units they are possibly visiting. This can help to not
only enhance performance of the model by tweaking it, but also helps improve
other functionalities of the model such as physician assignment and determination
of time of VTE occurrence.
VTE Risk Assessment:
‐ Increases the scope of the risk assessment model to go beyond the hospital
admissions and understand how hospital care effects the risk of getting a
blood clot even after hospital discharge.
‐ Calculates the risk of acquiring a blood clot as a function of time, to be able
to conditionally calculate the risk of the VTE depending on how long a patient
has been in the hospital.
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APPENDIX
Cancer ICD 9 List ‐ Neoplasms (140–239)
 Malignant neoplasm of lip, oral cavity, and pharynx (140–149)
 (140) Malignant neoplasm of lip
 (141) Malignant neoplasm of tongue
 (142) Malignant neoplasm of major salivary glands
 (143) Malignant neoplasm of gum
 (144) Malignant neoplasm of floor of mouth
 (145) Malignant neoplasm of other and unspecified parts of mouth
 (146) Malignant neoplasm of oropharynx
 (147) Malignant neoplasm of nasopharynx
 (148) Malignant neoplasm of hypopharynx
 (149) Malignant neoplasm of other and ill‐defined sites within the lip
 Malignant neoplasm of digestive organs and peritoneum (150–159)
 (150) Malignant neoplasm of esophagus
 (151) Malignant neoplasm of stomach
 (152) Malignant neoplasm of small intestine, including duodenum
 (153) Malignant neoplasm colon
 (154) Malignant neoplasm of rectum, rectosigmoid junction, and anus
 (155) Malignant neoplasm of liver and intrahepatic bile ducts
 (156) Malignant neoplasm of gallbladder and extrahepatic bile ducts
 (157) Malignant neoplasm of pancreas
 (158) Malignant neoplasm of retroperitoneum and peritoneum
 (159) Malignant neoplasm of other and ill‐defined sites within the
 Malignant neoplasm of respiratory and intrathoracic organs (160–165)
 (160) Malignant neoplasm of nasal cavities, middle ear, and accessory
sinuses
 (161) Malignant neoplasm of larynx
 (162) Malignant neoplasm of trachea, bronchus, and lung
o (162.0) Trachea
o (162.2) Main bronchus
o (162.3) Upper lobe, bronchus or lung
o (162.4) Middle lobe, bronchus or lung
o (162.5) Lower lobe, bronchus or lung
o (162.8) Other parts of bronchus or lung
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o (162.9) Bronchus and lung, unspecified
 (163) Malignant neoplasm of pleura
 (164) Malignant neoplasm of thymus, heart, and mediastinum
 (165) Malignant neoplasm of other and ill‐defined sites within the
respiratory system and intrathoracic organs
 Malignant neoplasm of bone, connective tissue, skin, and breast (170–175)
 (170) Malignant neoplasm of bone and articular cartilage
 (170.9) Malignant neoplasm of bone and articular cartilage, site
unspecified
o Ewing's sarcoma
o Osteosarcoma
o Chondrosarcoma
 (171) Malignant neoplasm of connective and other soft tissue
 Rhabdomyosarcoma
 (172) Malignant melanoma of skin
 (173) Other malignant neoplasm of skin
 (174) Malignant neoplasm of female breast
 (175) Malignant neoplasm of male breast
 Kaposi's sarcoma (176–176)
 (176) Kaposi's sarcoma
o (176.0) Kaposi's sarcoma skin
o (176.1) Kaposi's sarcoma soft tissue
o (176.2) Kaposi's sarcoma palate
o (176.3) Kaposi's sarcoma gastrointestinal sites
o (176.4) Kaposi's sarcoma
o (176.5) Kaposi's sarcoma lymph nodes
o (176.8) Kaposi's sarcoma other specified sites
o (176.9) Kaposi's sarcoma unspecified site
 Malignant neoplasm of genitourinary organs (179–189)
 (179) Malignant neoplasm of uterus, part unspecified
 (180) Malignant neoplasm of cervix uteri
 (181) Malignant neoplasm of placenta
 (182) Malignant neoplasm of body of uterus
o (182.0) Corpus uteri, except isthmus
o Endometrial cancer
 (183) Malignant neoplasm of ovary and other uterine adnexa
 (184) Malignant neoplasm of other and unspecified female genital organs
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(185) Malignant neoplasm of prostate
(186) Malignant neoplasm of testis
(187) Malignant neoplasm of penis and other male genital organs
(188) Malignant neoplasm of bladder
(189) Malignant neoplasm of kidney and other and unspecified urinary
organs
o (189.0) Kidney, except pelvis
o Renal cell carcinoma
 Malignant neoplasm of other and unspecified sites (190–199)
 (190) Malignant neoplasm of eye
 (191) Malignant neoplasm of brain
 (192) Malignant neoplasm of other and unspecified parts of nervous
system
o (192.0) Cranial nerve
o (192.1) Cerebral meninges
o Meningioma
o (192.2) Spinal cord
o (192.3) Spinal meninges
 (193) Malignant neoplasm of thyroid gland
 (194) Malignant neoplasm of other endocrine glands and related
structures
 (195) Malignant neoplasm of other and ill‐defined sites
 (196) Secondary and unspecified malignant neoplasm of lymph nodes
 (197) Secondary malignant neoplasm of respiratory and digestive systems
 (198) Secondary malignant neoplasm of other specified sites
 (199) Malignant neoplasm without specification of site
 Malignant neoplasm of lymphatic and hematopoietic tissue (200–208)
 (200) Lymphosarcoma and reticulosarcoma
o (200.0) Reticulosarcoma
o (200.1) Lymphosarcoma
o (200.2) Burkitt's tumor or lymphoma
o (200.3) Marginal zone lymphoma
o (200.4) Mantle cell lymphoma
o (200.5) Primary central nervous system lymphoma
o (200.6) Anaplastic large cell lymphoma
o (200.7) Large cell lymphoma
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o (200.8) Other named variants of lymphosarcoma and
reticulosarcoma
 (201) Hodgkin's disease
 (202) Other malignant neoplasms of lymphoid and histiocytic tissue
o (202.0) Nodular lymphoma
o (202.1) Mycosis fungoides
o (202.2) Sézary's disease
o (202.3) Malignant histiocytosis
o (202.4) Leukemic reticuloendotheliosis (commonly called hairy cell
leukemia)
o (202.5) Letterer‐Siwe disease
o (202.6) Malignant mast cell tumors
o (202.7) Peripheral T‐cell lymphoma
o (202.8) Other lymphomas
o (202.9) Other and unspecified malignant neoplasms of lymphoid
and histiocytic tissue
 (203) Multiple myeloma and immunoproliferative neoplasms
 (203.0) Multiple myeloma
 (204) Lymphoid leukemia
o (204.0) Acute lymphoblastic leukemia
o (204.1) Chronic lymphocytic leukemia
 (205) Myeloid leukemia
o (205.0) Acute myelogenous leukemia
o (205.1) Chronic myelogenous leukemia
 (206) Monocytic leukemia
 (207) Other specified leukemia
o (207.0) Acute erythremia and erythroleukemia
o (207.1) Chronic erythremia
o (207.2) Megakaryocytic leukemia
 (208) Leukemia of unspecified cell type
 Neuroendocrine tumors (209–209)
 (209) Neuroendocrine tumors
o (209.0) Malignant carcinoid tumors of the small intestine
o (209.1) Malignant carcinoid tumors of the appendix, large intestine,
and rectum
o (209.2) Malignant carcinoid tumors of other and unspecified sites
o (209.3) Malignant poorly differentiated neuroendocrine carcinoma
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o (209.4) Benign carcinoid tumors of the small intestine
o (209.5) Benign carcinoid tumors of the appendix, large intestine,
and rectum
o (209.6) Benign carcinoid tumors of other and unspecified sites
 Benign neoplasms (210–229)
 (210) Benign neoplasm of lip, oral cavity, and pharynx
 (211) Benign neoplasm of other parts of digestive system
o (211.3) Colon
o Familial adenomatous polyposis
 (212) Benign neoplasm of respiratory and intrathoracic organs
o (212.0) Nasal cavities middle ear and accessory sinuses
o (212.1) Larynx
o (212.2) Trachea
o (212.3) Bronchus and lung
o (212.4) Pleura
o (212.5) Mediastinum
o (212.6) Thymus
o (212.7) Heart
o Myxoma
o Rhabdomyoma
 (213) Benign neoplasm of bone and articular cartilage
o (213.9) Bone and articular cartilage, site unspecified
o Chondroma
 (214) Lipoma
 (215) Other benign neoplasm of connective and other soft tissue
 (216) Benign neoplasm of skin
 Melanocytic nevus
 (217) Benign neoplasm of breast
 (218) Uterine leiomyoma
 (219) Other benign neoplasm of uterus
 (220) Benign neoplasm of ovary
 (221) Benign neoplasm of other female genital organs
 (222) Benign neoplasm of male genital organs
 (223) Benign neoplasm of kidney and other urinary organs
 (224) Benign neoplasm of eye
 (225) Benign neoplasm of brain and other parts of nervous system
 (226) Benign neoplasm of thyroid glands
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 (227) Benign neoplasm of other endocrine glands and related structures
 (228) Hemangioma and lymphangioma, any site
o (228.0) Hemangioma, any site
o (228.1) Lymphangioma, any site
 (229) Benign neoplasm of other and unspecified sites
 Carcinoma in situ (230–234)
 (230) Carcinoma in situ of digestive organs
 (231) Carcinoma in situ of respiratory system
 (232) Carcinoma in situ of skin
 (233) Carcinoma in situ of breast and genitourinary system
 (234) Carcinoma in situ of other and unspecified sites
 Neoplasms of uncertain behavior (235–238)
 (235) Neoplasm of uncertain behavior of digestive and respiratory systems
 (236) Neoplasm of uncertain behavior of genitourinary organs
 (237) Neoplasm of uncertain behavior of endocrine glands and nervous
system
o (237.0) Pituitary gland and craniopharyngeal duct
o Pituitary adenoma
o (237.7) Neurofibromatosis
 (238) Neoplasm of uncertain behavior of other and unspecified sites and
tissues
o (238.4) Polycythemia vera
 Neoplasms of unspecified nature (239–239)
 (239) Neoplasms of unspecified nature
o (239.2) Skin, soft tissue neoplasm, unspecified

Cancer ICD 10 List
 (C00–C14) Malignant neoplasms, lip, oral cavity and pharynx
 (C00) Malignant neoplasm of lip
 (C01) Malignant neoplasm of base of tongue
 (C02) Malignant neoplasm of other and unspecified parts of tongue
 (C03) Malignant neoplasm of gum
 (C04) Malignant neoplasm of floor of mouth
 (C05) Malignant neoplasm of palate
 (C06) Malignant neoplasm of other and unspecified parts of mouth
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(C07) Malignant neoplasm of parotid gland
(C08) Malignant neoplasm of other and unspecified major salivary glands
(C09) Malignant neoplasm of tonsil
(C10) Malignant neoplasm of oropharynx
(C11) Malignant neoplasm of nasopharynx
(C12) Malignant neoplasm of piriform sinus
(C13) Malignant neoplasm of hypopharynx
(C14) Malignant neoplasm of other and ill‐defined sites in the lip, oral
cavity and pharynx
 (C15–C26) Malignant neoplasms, digestive organs
 (C15) Malignant neoplasm of Esophagus
 (C16) Malignant neoplasm of Stomach
o (C16.0) Cardia
o (C16.1) Fundus of stomach
o (C16.2) Body of stomach
o (C16.3) Pyloric antrum
o (C16.4) Pylorus
o (C16.5) Lesser curvature of stomach, unspecified
o (C16.6) Greater curvature of stomach, unspecified
o (C16.8) Overlapping lesion of stomach
o (C16.9) Stomach, unspecified
 (C17) Malignant neoplasms of small intestine
o (C17.0) Duodenum
o (C17.1) Jejunum
o (C17.2) Ileum
o (C17.3) Meckel's diverticulum
o (C17.8) Overlapping lesion of small intestine
o (C17.9) Small intestine, unspecified
 (C18) Malignant neoplasm of colon
o (C18.0) Caecum
o (C18.1) Appendix
o (C18.2) Ascending colon
o (C18.3) Hepatic flexure
o (C18.4) Transverse colon
o (C18.5) Splenic flexure
o (C18.6) Descending colon
o (C18.7) Sigmoid colon
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o (C18.8) Overlapping lesion of colon
o (C18.9) Colon, unspecified
 (C19) Malignant neoplasm of rectosigmoid junction
 (C20) Malignant neoplasm of rectum
 (C21) Malignant neoplasms of anus and anal canal
 (C22) Malignant neoplasms of liver and intrahepatic bile ducts
o (C22.0) Liver cell carcinoma
o (C22.1) Intrahepatic bile duct carcinoma
o (C22.2) Hepatoblastoma
o (C22.3) Angiosarcoma of liver
o (C22.4) Other sarcomas of liver
o (C22.7) Other specified carcinomas of liver
o (C22.9) Liver, unspecified
 (C23) Malignant neoplasm of gallbladder
 (C24) Malignant neoplasm of other and unspecified parts of biliary tract
 (C25) Malignant neoplasm of pancreas
 (C25.0) Head of pancreas
o (C25.1) Body of pancreas
o (C25.2) Tail of pancreas
o (C25.3) Pancreatic duct
o (C25.4) Endocrine pancreas
o (C25.7) Other parts of pancreas
o (C25.8) Overlapping lesion of pancreas
o (C25.9) Pancreas, unspecified
 (C26) Malignant neoplasms of other and ill‐defined Digestive Organs
 (C30–C39) Malignant neoplasms, respiratory system and intrathoracic organs
 (C30) Malignant neoplasm of nasal cavity and middle ear
o (C30.0) Nasal cavity
o (C30.1) Middle ear
 (C31) Malignant neoplasm of accessory sinuses
 (C32) Malignant neoplasm of larynx
 (C33) Malignant neoplasm of trachea
 (C34) Malignant neoplasm of bronchus and lung
o (C34.0) Main bronchus
o (C34.1) Upper lobe, bronchus or lung
o Pancoast tumor
o (C34.2) Middle lobe, bronchus or lung
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o (C34.3) Lower lobe, bronchus or lung
o (C34.8) Overlapping lesion of bronchus and lung
 (C37) Malignant neoplasm of thymus
 (C38) Malignant neoplasm of heart, mediastinum and pleura
o (C38.0) Heart
o (C38.1) Anterior mediastinum
o (C38.2) Posterior mediastinum
o (C38.3) Mediastinum, part unspecified
o (C38.4) Pleura
o (C38.8) Overlapping lesion of heart, mediastinum and pleura
 (C39) Malignant neoplasms of other and ill‐defined sites in respiratory
system and intrathoracic organs
 (C40–C41) Malignant neoplasms, bone and articular cartilage
 (C40) Malignant neoplasm of bone and articular cartilage of limbs
 (C41) Malignant neoplasm of bone and articular cartilage of other and
unspecified sites
 (C43–C44) Malignant neoplasms, skin
 (C43) Malignant melanoma of Skin
 (C44) Other malignant neoplasms of skin
 (C45–C49) Malignant neoplasms, connective and soft tissue
 (C45) Mesothelioma
 (C46) Kaposi's Sarcoma
 (C47) Malignant neoplasm of peripheral nerves and autonomic nervous
system
 (C48) Malignant neoplasm of retroperitoneum and peritoneum
o (C48.0) Retroperitoneum
o (C48.1) Specified parts of peritoneum
o (C48.2) Peritoneum, unspecified
 (C49) Malignant neoplasm of other connective and soft tissue
o C49.M10 Malignant fibrous histiocytoma
o C49.M12 Atypical fibroxanthoma
o C49.M20 Haemangiopericytoma
o C49.M22 Angioendotheliomatosis, malignant
o C49.M24 Dermatofibrosarcoma protruberans
o C49.M30 Bednar tumour
o C49.M40 Sarcoma of skin
o C49.M42 Fibrosarcoma
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o C49.M44 Schwannoma, malignant
o C49.M48 Leiomyosarcoma
o C49.M50 Rhabdomyosarcoma
o C49.M54 Myxofibrosarcoma
o C49.M60 Angiosarcoma, cutaneous
o C49.M70 Lymphangiosarcoma
(C50–C58) Malignant neoplasms, breast and female genital organs
 (C50) Malignant neoplasm of breast
 (C51) Malignant neoplasm of vulva
 (C52) Malignant neoplasm of vagina
 (C53) Malignant neoplasm of cervix uteri
 (C54) Malignant neoplasm of corpus uteri
o (C54.1) Endometrial cancer
 (C55) Malignant neoplasm of uterus, part unspecified
 (C56) Malignant neoplasm of ovary
 (C57) Malignant neoplasms of other and unspecified female and genital
organs
 (C58) Malignant neoplasm of placenta
o Choriocarcinoma
o Chorionepithelioma NOS
(C60–C63) Malignant neoplasms of male genital organs
 (C60) Malignant neoplasm of penis
 (C61) Malignant neoplasm of prostate
 (C62) Malignant neoplasm of testis
 (C63) Malignant neoplasm of other and unspecified male genital organs
(C64–C68) Malignant neoplasms, urinary organs
 (C64) Malignant neoplasm of kidney, except renal pelvis
 Wilms' tumor
 (C65) Malignant neoplasm of renal pelvis
 (C66) Malignant neoplasm of ureter
 (C67) Malignant neoplasm of bladder
 (C68) Malignant neoplasm of other and unspecified urinary organs
(C69–C72) Malignant neoplasms, eye, brain and central nervous system
 (C69) Malignant neoplasms of eye and adnexa
o (C69.0) Conjunctiva
o (C69.1) Cornea
o (C69.2) Retina
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o Retinoblastoma
o (C69.3) Choroid
o (C69.4) Ciliary body
o (C69.5) Lacrimal gland and duct
o (C69.6) Orbit
o (C69.7) Overlapping lesion of eye and adnexa
 (C70) Malignant neoplasm of meninges
o (C70.0) Cerebral meninges
o (C70.1) Spinal meninges
 (C71) Malignant neoplasm of brain
o (C71.0) Cerebrum, except lobes and ventricles
o (C71.1) Frontal lobe
o (C71.2) Temporal lobe
o (C71.3) Parietal lobe
o (C71.4) Occipital lobe
o (C71.5) Cerebral ventricle
o (C71.6) Cerebellum
o (C71.7) Brain stem
o (C71.8) Overlapping lesion of brain
o (C71.9) Brain, unspecified
 (C72) Malignant neoplasm of spinal cord, cranial nerves and other parts of
central nervous system
o (C72.0) Spinal cord
o (C72.1) Cauda equina
o (C72.2) Olfactory nerve
o (C72.3) Optic nerve
o (C72.4) Acoustic nerve
o (C72.5) Other and unspecified cranial nerves
o (C72.8) Overlapping lesion of brain and other parts of central
nervous system
o (C72.9) Central nervous system, unspecified
 (C73–C75) Malignant neoplasms, endocrine glands and related structures
 (C73) Malignant neoplasm of thyroid gland
 (C74) Malignant neoplasm of adrenal gland
o (C74.0) Cortex of adrenal gland
o (C74.1) Medulla of adrenal gland
o Pheochromocytoma
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o (C74.9) Adrenal gland, unspecified
o Neuroblastoma, NOS
 (C75) Malignant neoplasm of other endocrine glands and related
structures
 (C76–C80) Malignant neoplasms, secondary and ill‐defined
 (C76) Malignant neoplasm of other and ill‐defined sites
o (C76.0) Langerhans' cell histiocytosis, not elsewhere classified
o (C76.1) Haemophagocytic lymphohistiocytosis
o (C76.2) Haemophagocytic syndrome, infection‐associated
o (C76.3) Other histiocytosis syndromes
 (C77) Secondary and unspecified malignant neoplasm of lymph nodes
 (C78) Secondary malignant neoplasm of respiratory and digestive organs
 (C79) Secondary malignant neoplasm of other sites
 (C80) Malignant neoplasm without specification of site
 (C81–C96) Malignant neoplasms, stated or presumed to be primary, of
lymphoid, haematopoietic and related tissue
 (C81) Hodgkin's Disease
o (C81.0) Lymphocytic predominance
o (C81.1) Nodular sclerosis
o (C81.2) Mixed cellularity
o (C81.3) Lymphocytic depletion
 (C82) Follicular non‐Hodgkin's lymphoma (nodular)
o (C82.0) Small cleaved cell, follicular
o (C82.1) Mixed small cleaved and large cell, follicular
o (C82.2) Large cell, follicular
 (C83) Diffuse non‐Hodgkin's lymphoma
o (C83.0) small cell (diffuse)
o (C83.1) Small cleaved cell (diffuse)
o (C83.2) Mixed small and large cell (diffuse)
o (C83.3) large cell (diffuse)
o (C83.4) Immunoblastic (diffuse)
o (C83.5) Lymphoblastic (diffuse)
o (C83.6) Undifferentiated (diffuse)
o (C83.7) Burkitt's tumour
 (C84) Peripheral and cutaneous T‐cell lymphomas
o (C84.0) Mycosis fungoides
o (C84.1) Sézary's disease
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o (C84.2) T‐zone lymphoma
o (C84.3) Lymphoepitheliod lymphoma
o (C84.4) Peripheral T‐cell lymphoma
(C85) Other and unspecified types of non‐Hodgkin's lymphoma
o (C85.0) Lymphosarcoma
o (C85.1) B‐cell lymphoma, unspecified
(C88) Malignant immunoproliferative diseases
o (C88.0) Waldenström's macroglobulinaemia
o (C88.1) Alpha heavy chain disease
o (C88.2) Gamma heavy chain disease
o (C88.3) Immunoproliferative small intestinal disease
(C90) Multiple myeloma and malignant plasma cell neoplasms
o (C90.0) Multiple myeloma
o (C90.1) Plasma cell leukemia
o (C90.2) Plasmacytoma, extramedullary
(C91) Lymphoid leukemia
o (C91.0) Acute lymphoblastic leukemia
o (C91.1) Chronic lymphocytic leukemia
o (C91.4) Hairy cell leukemia
(C92) Myeloid leukemia
o (C92.0) Acute myeloid leukemia
o (C92.1) Chronic myeloid leukemia
o (C92.2) Subacute myeloid leukemia
o (C92.3) Myeloid sarcoma
o Chloroma
o Granulocytic sarcoma
o (C92.4) Acute promyelocytic leukemia
o (C92.5) Acute myelomonocytic leukemia
(C93) Monocytic leukemia
o (C93.0) Acute monocytic leukemia
o (C93.1) Chronic monocytic leukemia
o (C93.2) Subacute monocytic leukemia
(C94) Other leukemias of specified cell type
o (C94.0) Acute erythraemia and erythroleukemia
o Di Guglielmo's disease
o (C94.1) Chronic erythraemia
o (C94.2) Acute megakaryoblastic leukemia
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o (C94.3) Mast cell leukemia
o (C94.4) Acute panmyelosis
o (C94.5) Acute myelofibrosis
o (C94.7) Other specified leukemias
 (C95) Leukemia of unspecified cell type
 (C95.0) Acute leukemia of unspecified cell type
 (C95.1) Chronic leukemia of unspecified cell type
 (C95.2) Subacute leukemia of unspecified cell type
 (C95.7) Other leukemia of unspecified cell type
 (C95.9) Leukemia, unspecified
 (C96) Other and unspecified malignant neoplasms of lymphoid,
haematopoietic and related tissue
 (C96.0) Letterer‐Siwe disease
 (C96.1) Malignant histiocytosis
 (C96.2) Malignant mast cell tumour
 Malignant mastocytosis
 (C96.3) True histiocytic lymphoma
 (C96.7) Other specified malignant neoplasms of lymphoid,
haematopoietic and related tissue
 (C96.9) Malignant neoplasm of lymphoid, haematopoietic and related
tissue, unspecified
 (C97) Malignant neoplasms of independent (primary) multiple sites
Previous VTE ICD 9 List
 (415.1) Pulmonary embolism and infarction
 (415.11) Iatrogenic pulmonary embolism and infarction
 (415.13) Saddle embolus of pulmonary artery
 (451.11) Phlebitis and thrombophlebitis of femoral vein (deep)
(superficial)
 (415.19) Phlebitis and thrombophlebitis of deep veins of lower
extremities, other
 (451.2) Phlebitis and thrombophlebitis of lower extremities, unspecified
 (451.81) Phlebitis and thrombophlebitis of iliac vein
 (451.9) Phlebitis and thrombophlebitis of unspecified site
 (453.4) Acute venous embolism and thrombosis of deep vessels of lower
extremity
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 (453.40) Acute venous embolism and thrombosis of deep vessels of lower
extremity
 (453.41) Acute venous embolism and thrombosis of deep vessels of
proximal lower extremity
 (453.42) Acute venous embolism and thrombosis of deep vessels of distal
lower extremity
 (453.8) Acute venous embolism and thrombosis of other specified veins
 (453.9) Other venous embolism and thrombosis of unspecified site
Previous VTE ICD 10 List
 (I80.1) Phlebitis and thrombophlebitis of femoral vein
 (I80.10) Phlebitis and thrombophlebitis of unspecified femoral vein
 (I80.11) Phlebitis and thrombophlebitis of right femoral vein
 (I80.12) Phlebitis and thrombophlebitis of left femoral vein
 (I80.13) Phlebitis and thrombophlebitis of bilateral femoral vein
 (I80.20) Phlebitis and thrombophlebitis of unspecified deep vessels of lower
extremities
 (I80.201) Phlebitis and thrombophlebitis of unspecified deep vessels of
right lower extremity
 (I80.202) Phlebitis and thrombophlebitis of unspecified deep vessels of
left lower extremity
 (I80.203) Phlebitis and thrombophlebitis of unspecified deep vessels of
bilateral lower extremity
 (I80.209) Phlebitis and thrombophlebitis of unspecified deep vessels of
unspecified lower extremity
 (I80.21) Phlebitis and thrombophlebitis of iliac vein
 (I80.211) Phlebitis and thrombophlebitis of right iliac vein
 (I80.212) Phlebitis and thrombophlebitis of left iliac vein
 (I80.213) Phlebitis and thrombophlebitis of bilateral iliac vein
 (I80.219) Phlebitis and thrombophlebitis of unspecified iliac vein
 (I80.22) Phlebitis and thrombophlebitis of popliteal vein
 (I80.221) Phlebitis and thrombophlebitis of right popliteal vein
 (I80.222) Phlebitis and thrombophlebitis of left popliteal vein
 (I80.223) Phlebitis and thrombophlebitis of bilateral popliteal vein
 (I80.229) Phlebitis and thrombophlebitis of unspecified popliteal vein
 I80.23 Phlebitis and thrombophlebitis of tibial vein
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 (I80.231) Phlebitis and thrombophlebitis of right tibial vein
 (I80.232) Phlebitis and thrombophlebitis of left tibial vein
 (I80.233) Phlebitis and thrombophlebitis of bilateral tibial vein
 (I80.239) Phlebitis and thrombophlebitis of unspecified tibial vein
(I80.29) Phlebitis and thrombophlebitis of other deep vessels of lower
extremities
 (I80.291) Phlebitis and thrombophlebitis of other deep vessels of right
lower extremity
 (I80.292) Phlebitis and thrombophlebitis of other deep vessels of left
lower extremity
 (I80.293) Phlebitis and thrombophlebitis of other deep vessels of lower
extremity, bilateral
 (I80.299) Phlebitis and thrombophlebitis of other deep vessels of
unspecified lower extremity
(I82.4) Acute embolism and thrombosis of unspecified deep veins of lower
extremity
 (I82.401) Acute embolism and thrombosis of unspecified deep veins of
right lower extremity
 (I82.402) Acute embolism and thrombosis of unspecified deep veins of left
lower extremity
 (I82.403) Acute embolism and thrombosis of unspecified deep veins of
bilateral lower extremity
 (I82.409) Acute embolism and thrombosis of unspecified deep veins of
unspecified lower extremity
 (I82.411) Acute embolism and thrombosis of right femoral vein
 (I82.412) Acute embolism and thrombosis of left femoral vein
 (I82.413) Acute embolism and thrombosis of bilateral femoral vein
 (I82.419) Acute embolism and thrombosis of unspecified femoral vein
(I82.42) Acute embolism and thrombosis of iliac vein
 (I82.421) Acute embolism and thrombosis of right iliac vein
 (I82.422) Acute embolism and thrombosis of left iliac vein
 (I82.423) Acute embolism and thrombosis of bilateral iliac vein
 (I82.429) Acute embolism and thrombosis of unspecified iliac vein
(I82.43) Acute embolism and thrombosis of popliteal vein
 (I82.431) Acute embolism and thrombosis of right popliteal vein
 (I82.432) Acute embolism and thrombosis of left popliteal vein
 (I82.433) Acute embolism and thrombosis of bilateral popliteal vein
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 (I82.439) Acute embolism and thrombosis of unspecified popliteal vein
(I82.44) Acute embolism and thrombosis of tibial vein
 (I82.441) Acute embolism and thrombosis of right tibial vein
 (I82.442) Acute embolism and thrombosis of left tibial vein
 (I82.443) Acute embolism and thrombosis of bilateral tibial vein
 (I82.449) Acute embolism and thrombosis of unspecified tibial vein
(I82.49) Acute embolism and thrombosis of other specified deep vein of
lower extremity
 (I82.491) Acute embolism and thrombosis of other specified deep vein of
right lower extremity
 (I82.492) Acute embolism and thrombosis of other specified deep vein of
left lower extremity
 (I82.493) Acute embolism and thrombosis of other specified deep vein of
bilateral lower extremity
 (I82.499) Acute embolism and thrombosis of other specified deep vein of
unspecified lower extremity
(I82.4Y) Acute embolism and thrombosis of unspecified deep veins of
proximal lower extremity
 (I82.4Y1) Acute embolism and thrombosis of unspecified deep veins of
right proximal lower extremity
 (I82.4Y2) Acute embolism and thrombosis of unspecified deep veins of left
proximal lower extremity
 (I82.4Y3) Acute embolism and thrombosis of unspecified deep veins of
bilateral proximal lower extremity
 (I82.4Y9) Acute embolism and thrombosis of unspecified deep veins of
unspecified proximal lower extremity
(I82.4Z) Acute embolism and thrombosis of unspecified deep veins of distal
lower extremity
 (I82.4Z1) Acute embolism and thrombosis of unspecified deep veins of
right distal lower extremity
 (I82.4Z2) Acute embolism and thrombosis of unspecified deep veins of left
distal lower extremity
 (I82.4Z3) Acute embolism and thrombosis of unspecified deep veins of left
distal bilateral extremity
 (I82.4Z9) Acute embolism and thrombosis of unspecified deep veins of
unspecified distal lower extremity
 (I26.02) Saddle embolus of pulmonary artery with acute cor pulmonale
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 (I26.09) Other pulmonary embolism with acute cor pulmonale
 (I26.92) Saddle embolus of pulmonary artery without acute cor pulmonale
 (I26.99) Other pulmonary embolism without acute cor pulmonale
Acute Rheumatologic Disorder ICD9 List































(390) RHEUMATIC FEVER WITHOUT HEART INVOLVEMENT
(391.0) ACUTE RHEUMATIC PERICARDITIS
(391.1) ACUTE RHEUMATIC ENDOCARDITIS
(391.2) ACUTE RHEUMATIC MYOCARDITIS
(391.8) OTHER ACUTE RHEUMATIC HEART DISEASE
(391.9) ACUTE RHEUMATIC HEART DISEASE UNSPECIFIED
(392.0) RHEUMATIC CHOREA WITH HEART INVOLVEMENT
(392.9) RHEUMATIC CHOREA WITHOUT HEART INVOLVEMENT
(393) CHRONIC RHEUMATIC PERICARDITIS
(394.0) MITRAL STENOSIS
(394.1) RHEUMATIC MITRAL INSUFFICIENCY
(394.2) MITRAL STENOSIS WITH INSUFFICIENCY
(394.9) OTHER AND UNSPECIFIED MITRAL VALVE DISEASES
(395.0) RHEUMATIC AORTIC STENOSIS
(395.1) RHEUMATIC AORTIC INSUFFICIENCY
(395.2) RHEUMATIC AORTIC STENOSIS WITH INSUFFICIENCY
(395.9) OTHER AND UNSPECIFIED RHEUMATIC AORTIC DISEASES
(396.0) MITRAL VALVE STENOSIS AND AORTIC VALVE STENOSIS
(396.1) MITRAL VALVE STENOSIS AND AORTIC VALVE INSUFFICIENCY
(396.2) MITRAL VALVE INSUFFICIENCY AND AORTIC VALVE STENOSIS
(396.3) MITRAL VALVE INSUFFICIENCY AND AORTIC VALVE INSUFFICIENCY
(396.8) MULTIPLE INVOLVEMENT OF MITRAL AND AORTIC VALVES
(396.9) MITRAL AND AORTIC VALVE DISEASES UNSPECIFIED
(397.0) DISEASES OF TRICUSPID VALVE
(397.1) RHEUMATIC DISEASES OF PULMONARY VALVE
(397.9) RHEUMATIC DISEASES OF ENDOCARDIUM VALVE UNSPECIFIED
(398.0) RHEUMATIC MYOCARDITIS
(398.90) RHEUMATIC HEART DISEASE UNSPECIFIED
(398.91) RHEUMATIC HEART FAILURE (CONGESTIVE)
(398.99) OTHER RHEUMATIC HEART DISEASES
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(I00) Rheumatic fever without heart involvement
(I01) Rheumatic fever with heart involvement
(I02) Rheumatic chorea
(I05) Rheumatic mitral valve diseases
(I06) Rheumatic aortic valve diseases
(I07) Rheumatic tricuspid valve diseases
(I08) Multiple valve diseases
(I09) Other rheumatic heart diseases
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ABSTRACT
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Venous Thromboembolism (VTE) is a deadly disease and is considered as one of
the top reasons for avoidable hospital deaths in the United States and around the
world. Patients who survive this disease often must face life‐long complications
such as Post‐thrombotic syndrome (PTS), Chronic thromboembolic pulmonary
hypertension (CTPH), etc. Therefore, it is important to monitor and reduce the
number of VTE instances in hospitals. This study shows how Electronic Health
Records (EHRs) can be utilized to achieve this goal.
First, a new near real‐time VTE harm measurement model was developed. Not
only the developed model can deliver near real‐time results, but also it can
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outperform the existing PSI12 measurement model that uses administrative data
(sensitivity 84% vs. 38% and NPV 99% vs. 95%).
In the next step, Padua VTE risk assessment model was developed inside the EHR
to deliver real‐time VTE risk assessment. Retrospective data analysis was also
performed to show how another risk assessment model (IMPROVE) can be
developed inside EHR. Analysis were completed to show and compare the
effectiveness of each model.
Finally, the results of utilizing the developed models are presented in terms of
contributions to savings for the health system as well as the number of lives saved.
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